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I. Summary 
Interleukin-2 (IL-2) immunotherapy is an attractive approach for the treatment of advanced 
cancer. However, its short half-life and side effects have compromised its further 
development into the clinics. Via binding to its IL-2 receptor  (CD25) subunit, IL-2 exerts 
unwanted effects including stimulation of immunosuppressive regulatory T (Treg) cells and 
endothelial cell damage. Using a rational based approach, we developed a monoclonal 
antibody to human IL-2 (hIL-2), termed NARA1, blocking with high affinity the interaction 
of the cytokine with the CD25 receptor subunit. The structure of the hIL-2/NARA1 complex 
(IL-2cx) reveals that NARA1 perfectly overlaps with CD25. NARA1 binds to hIL-2 with 10-
fold higher affinity compared to CD25 favoring hIL-2 interaction with the dimeric IL-2 
receptor. In line with this, IL-2cx immunotherapy leads to potent anti-tumor immunity, by 
favoring the ratio of tumor-specific and polyclonal cytotoxic CD8+ T cells vs Treg cells, 
leading to less endothelial cell damage and increasing the half-life of the cytokine. IL-2cx 
significantly improves survival in transplantable and spontaneous metastatic melanoma 
models. These data warrant further development of NARA1. 
Despite potent and constant stimulation of the immune system upon IL-2cx therapy, cancer 
cells use several mechanisms to suppress the anti-tumor immune response and to become 
resistant. The molecular processes of tumor immune escape from immune surveillance remain 
poorly understood. We were able to show that different tumor immune escape mechanisms 
are controlled by the histone methyltransferase enhancer of zeste homologue 2 (Ezh2). During 
IL-2cx immunotherapy, Ezh2 expression increases in melanoma cells, particularly in areas 
rich in tumor-infiltrating lymphocytes. Ezh2 inhibit the transcription of molecules essential 
for proper tumor antigen presentation and promote a dedifferentiation program leading to 
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disease progression and metastasis. Ezh2 blockade reverses these effects in melanoma cells 
and synergizes with IL-2cx or anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-
4) immunotherapy to control tumor growth. Upon combinatorial treatment interferon--
producing CD8+ T cells selectively accumulate in the tumor site and maintain low 
programmed cell death protein 1 (PD-1) levels, accompanied by programmed death-ligand 1 
(PD-L1) downregulation on melanoma cells. On the other hand, immunosuppressive cells 
such as FoxP3+ CD4+ regulatory T cells and myeloid-derived suppressor cells fail to 
accumulate intratumorally. These data reveal the importance of Ezh2 playing a key role 
during tumor immune escape and indicate that combination of EZH2 blockade and 
immunotherapeutics might be considered for cancer therapy. 
  
 7 
 
II. Zusammenfassung 
Interleukin-2 Immuntherapie ist eine attraktive Strategie zur Behandlung von Krebs in 
fortgeschrittenen Stadien. Allerdings führt die Bindung von IL-2 an die -Untereinheit seines 
Rezeptors (auch CD25 genannt) zu ungewollten Nebenwirkungen, welche einerseits zur 
Stimulierung von immun-suppressiven regulatorischen T-Zellen (Treg-Zellen) und 
andererseits zu einer Schädigung des Endotheliums führt. Dank einer rationalen 
Vorgehensweise konnten wir einen monoklonalen Antikörper namens NARA1 entwickeln, 
der als hoch-affiner CD25-Imitator wirkt und so die Assoziation von IL-2 mit CD25 
verringert. Die Strukturaufklärung dieses neuen hIL-2/NARA1 Komplexes zeigte, dass 
NARA1 tatsächlich das CD25-Bindungsepitop von IL-2 besetzt, wodurch es zu einer sehr 
präzisen Überlappung der beiden Epitope kommt. Die Bindung von NARA1 an IL-2 erfolgt 
mit 10-fach höherer Affinität im Vergleich zu CD25 und führt zu hIL-2/NARA1 Komplexen 
(IL-2cx), die eine starke Präferenz hinsichtlich der Stimulierung von CD8+ T-Zellen aufweist, 
während die Stimulierung von Treg-Zellen und die schädliche Wirkung auf das Endothelium 
reduziert werden. Die Immuntherapie mit hIL-2/NARA1 Komplexen führt zu einer starken 
Anti-Tumor-Immunantwort durch die Proliferation von Tumor-speziefischen polyklonalen 
zytotoxischen CD8+ T-Zellen. Diese Therapie führt somit zu einer bedeutenden Verlängerung 
der Lebenserwartung in Mäusen, in welche entweder Melanomzellen injiziert wurden, oder in 
anderen Mäusen, welche spontan Melanome entwickeln. Diese Daten dienen als Basis für die 
Weiterentwicklung von NARA1. 
Trotz effizienter und konstanter Stimulierung des Immunsystems mittels IL-2cx entwickeln 
Tumorzellen verschiedene Mechanismen zur Resistenz gegen das Abtöten durch 
Immunsystem oder aber Tumorzellen unterdrücken das Immunsystem. Die molekularen 
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Prozesse, die zur Umgehung der Immunüberwachung des Tumors führen, sind bis jetzt nur 
unzureichend verstanden. Wir konnten zeigen, dass verschiedene Tumorzell-intrinsische 
und -extrinsische Mechanismen zur Überwindung einer Immunantwort durch die Histon-
Methyltransferase Enhancer of Zeste Homologue 2 (Ezh2) kontrolliert werden. Während der 
IL-2cx-Immuntherapie steigt die Expression von Ezh2 in Melanomzellen an, insbesondere in 
Bereichen des Tumors, die intensiv von Lymphozyten infiltriert wurden. Ezh2 fördert ein 
Dedifferenzierungsprogramm in Tumorzellen, welches an das Fortschreiten der Krankheit 
erinnert und die Unterdrückung von Schlüsselmolekülen der MHC/Antigen-Präsentation 
beinhaltet. Die Inaktivierung von Ezh2 macht diese Prozesse rückgängig und führt in 
Kombination mit IL-2cx- oder anti-CTLA-4-Immuntherapie zu einer erkenntlichen 
Verlangsamung des Tumorwachstums. Diese Anti-Tumor-Effekte hängen stark von 
Interferon--produzierenden CD8+ T-Zellen ab, die sich selektiv im Innern des Tumors 
anreichern. Zudem erhalten diese Zellen ein tiefes PD-1 Niveau aufrecht, während 
gleichzeitig die Expression von PD-L1 auf Melanomzellen herunter reguliert wird. Im 
Gegensatz dazu werden immun-suppresive FoxP3+ CD4+ Treg-Zellen und myeloide 
Suppressorzellen während der Kombinationstherapie bestehend aus Ezh2-Inhibition und IL-
2cx-Immuntherapie davon abgehalten in den Tumor einzudringen. Folglich fungiert Ezh2 als 
molekularer Schalter, der die Überwindung des Immunsystems durch den Tumor kontrolliert. 
Diese Erkenntnisse implizieren, dass die Blockade von EZH2 zusammen mit Immuntherapien 
für die Krebstherapie in Betracht gezogen werden könnte. 
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III. Introduction  
1. The immune system 
The immune system is a complex network of cells, tissues, lymphoid organs, and messengers, 
which work together in order to defend our body against pathogens and endogenous 
malignancies. Epithelial cell barriers form our first line of defense and prevent disease-
causing pathogens from invading our body. If pathogens manage to attach to epithelial cells or 
to cross the epithelial barriers, an immediate defense reaction will take place defined as the 
innate immune response comprising granulocytes, monocytes, macrophages, innate lymphoid 
cells, dendritic cells, the complement system, cytokines, chemokines, and acute phase 
proteins. Because this innate immune reaction has to occur within minutes, it is based on 
broadly specific pathogen receptors which recognize common structural features present on a 
variety of pathogens. However, this first line of defense is sometimes insufficient to overcome 
an infection. Higher organisms have therefore developed an adaptive immune system 
providing a highly specific defense against invaders, which the innate immune system fails to 
clear. Adaptive immune responses rely on immune cells featuring antigen receptors and 
develop within days in response to an infection. These receptor-bearing adaptive immune 
cells are retained after the pathogens are destroyed and form an immunological memory 
allowing fast detection and elimination of pathogens by memory lymphocytes upon a second 
encounter with the same pathogen [1, 2]. 
a) The innate immune system 
The initial adaptive immune response can take up to 4 to 7 days. Therefore the innate immune 
response plays an essential role in restraining rapid pathogen growth during this time. 
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Microorganisms such as bacteria able to cross our epithelial barriers are immediately sensed 
by phagocytic macrophages present in almost all tissues and able to mount an innate immune 
response. They express pattern-recognition receptors (PRRs) able to bind to a broad range of 
bacterial surface constituents triggering phagocytosis [3] and secrete important messenger 
molecules such as cytokines and chemokines, thus enabling the communication between cells 
and attracting other immune cells to the site of infections. This is the case for neutrophils and 
monocytes migrating from the blood stream into infected tissues. Neutrophils are a major type 
of innate cells observed during an infection, they express in analogy to macrophages, PRRs, 
and are able to engulf and destroy a variety of microorganisms. The released cytokines and 
chemokines initiate a state of inflammation in the infected tissue. Inflammation is 
characterized by an increased permeability of surrounding blood vessels, facilitating immune 
cell infiltration. In an immature state, dendritic cells (DCs) are also able to engulf pathogens 
but after maturation they function as specialized antigen presenting cells (APCs). This process 
will be further described below. 
The action of phagocytic cells is aided by the complement system which activates a cascade 
of proteolytic reactions on the surface of microorganism. The pathogens are thereby coated 
with fragments of complement components, which can be recognized by phagocytic 
receptors. At the same time other proteolytic fragments remain soluble and further promote 
the inflammatory state.  
Eosinophils are another cell type of the innate immune system containing cytosolic granules 
which, upon activation, release molecules such as reactive oxygen species leading to cell 
death [4]. Basophils and mast cells play an essential role in allergies due to the expression of 
high affinity receptors for IgE on their surface [5, 6]. 
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Importantly, innate immunity is not only based on phagocytosis of intracellular 
microorganisms because some pathogens can also exist outside the host cells. Natural killer 
(NK) cells have the ability to destroy infected and/or malignant cells using two mechanisms: 
The first relies on binding of their surface Fc receptors to immunoglobulin (Ig) G coated-
target cells followed by the release of cytotoxic granules onto the infected cell, a process 
which is known as antibody-dependent cellular cytotoxicity (ADCC). The second mechanism 
is based on the discrimination of normal cells from cells that have downregulated for example 
major histocompatibility complex (MHC) class I molecules as a result of a virus infection [7, 
8]. Innate lymphoid cells (ILCs) were recently identified as members of the lymphoid lineage. 
ILCs do not express surface markers associated with other immune cell lineages and do not 
respond in an antigen-specific manner. Instead, they play important functions in innate 
immune responses and in the regulation of homeostasis and inflammation. They are 
subdivided into three groups according to their cytokine profile: ILC1 (comprising also NK 
cells), ILC2, and ILC3 releasing type 1, type 2 and T helper (Th) 17 cell-associated cytokines 
(see below chapter on effector T cells for a more detailed description), respectively [9].  
b) The adaptive immune system 
The innate immune system is not only involved in the rapid elimination of pathogens but it is 
also essential for the activation of adaptive immunity in order to develop specific and long-
lasting immune responses. In analogy to macrophages and neutrophils, immature DCs can 
bind to bacterial surface components referred as pathogen-associated molecular patterns 
(PAMPs) through PRRs and Toll-like receptors (TLRs) triggering their maturation into APCs. 
Upon activation, DCs enter the lymphatic system and migrate to the nearby draining lymph 
nodes. After uptake of pathogen-derived antigens at the site of infection, expression levels of 
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MHC-I, MHC-II and co-stimulatory molecules are up-regulated allowing antigen presentation 
and priming of antigen-specific T cells through engagement with their respective antigen 
receptors and co-stimulation (co-stimulatory signals 1 and 2 described below). Additionally, 
DCs also secrete pro-inflammatory cytokines providing essential signals for the activation of 
adaptive immune cells, also called lymphocytes. Taken together, DCs are the most important 
type of APCs bridging innate and adaptive immunity [10]. 
We can subdivide lymphocytes in two categories, B and T lymphocytes. They both develop 
from lymphoid progenitor cells in the bone marrow. B cells mature in the bone marrow while 
T cells migrate to the thymus at an early stage. The specific and diverse production of antigen 
receptors in both cell types is the result of random recombination of four DNA fragments: 
variable (V), diversity (D), joining (J) and constant (C) regions by a set of enzymes containing 
the products of the recombination activating gene 1 (RAG1) and RAG2 [11]. T lymphocytes 
feature either of two forms of membrane-bound T cell receptors (TCR): TCRα/β or TCRγ/δ 
chains. The TCR forms a complex with the cluster of differentiation 3 (CD3) protein. The B 
cell receptor (BCR) is a form of membrane-bound monoclonal immunoglobulin; it binds the 
antigen and can internalize it playing the role of an APC. Even though gene rearrangement is 
similar for T and B cell receptors, they bind to antigens in a different manner. The TCR can 
only bind linear peptides associated with MHC-I or II, which have been previously processed 
by proteasomes within the APC. By contrast, B cells can bind intact antigens either in their 
soluble form or presented by APCs. The interplay of innate and adaptive immune cells via 
different cytokines, co-stimulatory molecules and antigen receptors is illustrated in Figure 1 
with the example of some Th cells subsets. A similar cross-talk also exists for cytotoxic T 
cells and B cells.  
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Figure 1 DCs: Bridging innate and adaptive immunity. Shown are cells of the innate 
immune system, including macrophages, mast cells, NK cells and dendritic cells (DC). T 
helper cells are shown as representatives of adaptive immune cells. Immature DC can be 
activated by pathogen-associated molecular patterns (PAMPs) or tissues factors (TF) to 
mature and activate naïve T cells. Adapted from [12]. 
The random nature of the TCR repertoire requires a tight regulation of the T cell maturation 
process to remove those cells bearing a TCR specific for an endogenous peptides. This 
maturation process occurs in several selection steps, termed positive and negative selection, 
which ensure that TCRs will only recognize a complex formed by a foreign peptide seated 
within the groove of an MHC molecule [13, 14]. All T cells binding to self-MHC are 
positively selected in the cortex of the thymus and pass into the cortico-medullary junction 
where the negative selection of self-reactive T cells occurs. The process of T cell selection 
generates self-tolerant T cells able to bind foreign antigens presented on self-MHC molecules 
[15, 16]. 
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Likewise, B lymphocytes will go through the process of central and peripheral tolerance in the 
bone marrow and in the periphery, which implicates that autoreactive B cells are eliminated 
via clonal deletion or B cell receptor editing. A new antibody repertoire is generated through 
somatic hypermutation when a B cell encounters an antigen, and only B cells binding with 
high affinity survive and become memory B cells [17].  
c) Antigen recognition by T cells 
The recognition of an antigen by the TCR is different for CD4+ and CD8+ T cells. CD4+ T 
cells exclusively recognize antigens presented in the context of an MHC-II molecule. This 
remains important since MHC-II molecules are only expressed by APCs including DCs, B 
cells and macrophages, able to engulf, digest and present peptides of exogenous pathogens. 
On the other hand, CD8+ T cells only recognize antigens presented on MHC-I. In this case, 
the peptide antigens originate from intracellular proteins (such as a tumor antigens) processed 
via intracellular pathways. The type of MHC molecules presenting the antigen therefore 
determines different T cell effector functions. Since all nucleated cells express MHC-I on 
their surface, any cell presenting foreign or mutated peptides can trigger the cytotoxic activity 
of CD8+ T cells. In contrast, CD4+ T cell activation by APCs leads to cytokine production, 
subdividing them into specific subtypes depending on the cytokine microenvironment. In 
order to induce T cell activation, two signals are required: First, engagement of the antigen-
MHC complex by the TCR which is associated with CD3 molecules that transmit signal 1 
into the cell. The second signal is provided by co-stimulatory molecules such as CD80/CD86 
on APC via co-stimulatory receptors like CD28 as shown Figure 2 [18]. In the absence of 
such co-stimulatory signals or in the presence of co-inhibitory signals, T cells will enter into 
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anergy or apoptosis. Prominent examples of co-inhibitory receptors are programmed death-1 
(PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).  
 
Figure 2. Co-stimulatory and co-inhibitory receptors on T cells. Upon interaction of the 
ligands present on APCs or tumor cells with their corresponding receptors on T cells, either a 
co-stimulatory (green arrows) or co-inhibitory (red arrows) signal is provided. Adapted from 
[19]. 
d) Effector T cells 
Two main types of effector T cells have been characterized, including CD4+ T helper (Th) 
cells and CD8+ cytotoxic T (Tc) cells. As mentioned above, Th cells are subdivided by the 
pattern of cytokine production driving expression of specific transcription factors. Th 1 
lymphocytes are essential in the cellular immune response and in host defense mechanisms to 
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kill intracellular pathogens. Within the Th 1 cytokines, interleukin 2 (IL-2) plays an essential 
role in mediating T cell proliferation [20]. Interferon-γ (IFN-γ) is also essential in activating 
macrophages and stimulates undifferentiated Th 0 cells to become Th 1 cells, while inhibiting 
Th 2 differentiation. Following this line, activated APCs will produce IL-12, a cytokine 
promoting the survival and growth of Th 1 lymphocytes. Instead, Th 2 cells mediate the 
activation and maintenance of the humoral response against extracellular pathogens. Within 
the Th 2 cytokines, IL-4 is essential in favoring antibody production by the induction of class-
switch recombination in B cells and promoting a positive feedback loop to increase Th 2 
differentiation. IL-6 mediates B cell maturation into plasma cells and plays a critical role in 
inflammation and autoimmunity, while IL-5 promotes the generation and proliferation of 
eosinophils [21]. Other Th immune subsets have been defined as IL-17 expressing T cells (Th 
17) promoting neutrophil recruitment and activation. Thus, Th 17 cells are important for the 
elimination of extracellular bacteria [22]. IL-9 expressing Th 9 cells which play an important 
role in asthma and IgE class switch recombination have been identified [23, 24]. Follicular 
helper T cells (T fh) are located in the B cell follicles of secondary lymphoid organs and are 
involved in B cell antigen presentation and their subsequent maturation in the germinal 
centers [25]. Forkhead box P3+ (Fox P3) CD25+ CD4+ regulatory T cells (Treg cells) are 
critical for the maintenance of immune cell homeostasis by producing immunosuppressive 
ligands and cytokines. As explained before, Tcs are the key effector T cell type for the 
elimination of infected or abnormal cells. They bind to their specific peptide-MHC complex 
and kill the target cells by different pathways:  
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 Perforins released from cytotoxic granules bind to the target cell’s membrane 
and form pores through which pro-apoptotic proteases (granzymes) can enter 
the target cell. 
 Fas ligand (FasL) expressed on the Tc's surface will bind to its receptor Fas 
expressed on target cells [26]. 
Both pathways will lead to activation of apoptotic mediators known as caspases [27]. 
Moreover, Tc produce cytokines such as tumor necrosis factor (TNF), lymphotoxins and IFN-
γ. Besides its role in the activation of macrophages [28], IFN-γ is also known for its ability to 
render adjacent cells resistant to infection and to upregulate the expression of MHC-I 
molecules and other proteins involved in peptide processing and loading onto MHC-I 
molecules.  
e) B cell development and antibodies 
B cell development starts in the bone marrow through the pro-B-cell, pre-B cell and immature 
B cell stages (IgM+ B cell). Bone marrow stromal cells provide secreted and cell surface 
factors promoting B cell maturation resulting in antigen-specific cells expressing a functional 
BCR repertoire, the diversity of which is ensured by the VDJ recombination process as 
previously described. At this immature stage, self-reactive B cells undergo receptor editing 
and clonal deletion. Non-self-reactive immature B cells will migrate from the bone marrow to 
the secondary lymphoid organs (spleen or lymph nodes) where they undergo maturation and 
become IgMlow IgDhigh B cells. Some cells are driven to become marginal zone B cells, 
located in the interface between the circulation and lymphoid tissue and able to provide fast 
responses mainly against blood-borne antigens [29]. B cells can interact with two kinds of 
antigens: thymus-dependent (TD) and thymus-independent (TI) antigens. In the case of TI 
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antigens, B cell activation occurs without involvement of Th cells. Co-stimulation is mainly 
provided by PRR signaling such as TLRs. B cells activated by TI antigens proliferate in the 
secondary lymphoid organs and differentiate into short-lived plasmablasts providing a fast but 
weak antibody response. In the case of TD antigens, most of mature B cells will be activated 
in the B cell follicles (crucial structures for T and B cell interaction) upon antigen binding. B 
cells will bind and engulf the antigen by BCR-mediated endocytosis, degrade and present to T 
fh via their MHC-II molecules.  T fh are then activated and provide co-stimulatory signals and 
cytokines essential for B cell activation such as CD40 ligand, IL-21, IL-4 and IL-6 [30]. After 
activation, some B cells can differentiate into short-lived plasmablasts providing an 
immediate but weak immune reaction through the secretion of IgM antibodies. Most of the 
activated B cells will form a germinal center where they will further expand while somatic 
hypermutation occurs. This step in B cell development is crucial because the introduction of 
additional mutations within the genes of the antigen-binding domains leads to affinity 
maturation of the BCR or to apoptosis in the case of disadvantageous mutations. Further 
selection, isotope class switching and differentiation will take place upon encounter of T fh 
and follicular dendritic cells resulting in the generation of memory and plasma cell precursors 
(plasmablasts) [31]. The final stages of differentiation into antibody-secreting plasma cells 
occur outside of the germinal center. Plasmablasts express high levels of surface Ig which can 
still switch their antibody isotype. By contrast, fully differentiated plasma cells have very low 
levels of surface Ig and class-switch recombination is considered complete in these cells. The 
generated memory B cells and plasma cells can migrate back to the bone marrow where they 
are responsible for long-term production of antibodies, which are secreted into the 
bloodstream (Figure 3).  
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Figure 3. B cell maturation. B cells are generated in the bone marrow and migrate to 
secondary lymphoid organs (spleen or lymph node). Some B cells will become marginal zone 
B cells but most of them will mature and differentiate in germinal centers (GC) upon antigen 
encounter. In the dark zone (DZ) of the GC, B cells will expand and BCR diversification 
takes place through somatic hypermutations. In the light zone (LZ) B cells undergo further 
selection resulting in isotype class switching and differentiation into memory B cells and 
plasmablasts. Antibody-producing plasma cells and memory B cells can home back to the 
bone marrow. T fh: follicular helper T cells; fDC: follicular dendritic cells. Adapted from [29, 
31]. 
The antibodies secreted by plasma cells are Y-shaped proteins, referred to as 
immunoglobulins (Ig), composed of two heavy and two light chains [32, 33]. Each of these 
chains has a variable region, containing the antigen binding site, and a constant region (Figure 
4). The constant region determines the effector mechanism used to destroy the pathogen. The 
variability of the amino acid sequences of the variable region is not random but precisely 
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organized. The greatest variability is located in the areas called hypervariable regions (HV) or 
complementarity-determining regions (CDRs) within the antigen-binding site. 
 
Figure 4. Structure of an Immunoglobulin (Ig). An Ig is composed by two identical light 
(L) and heavy (H) chains; each of them having a constant domain (C) and a variable domain 
(V). The heavy chain is composed of three constant domains (CH1, CH2 and CH3). Disulfide 
bonds link the two heavy chains in the hinge region and the light chains to the heavy chain. 
The antigen-binding part (Fv) of the Ig is formed by pairing VL and VH domains which bring 
together their CDRs resulting in the antibody's antigen-specificity. The interaction interface 
with effector molecules (such as C1 complex for the complement system or Fc receptors in 
immune cells) is located in the Fc part of the Ig. Adapted from [32].  
Humans express five different antibody isotypes or classes: IgG, IgM, IgD, IgA and IgE. 
They differ in their biochemical and serological properties - such as charge, size and solubility 
- and by their respective tissue distribution and function. Antibodies have the capacity to 
either neutralize the antigen by binding and inhibiting its function or recruit immune cells 
such as NK cells, macrophages and neutrophils expressing Fc receptors for IgG (FcγR) that 
are able to engulf and destroy the bound pathogen or tumor cell through ADCC or 
phagocytosis. Upon phagocytosis, DCs and other APCs can present the peptide antigens on 
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MHC-II for the activation of CD4+ T cells. Cross-presentation of peptides derived from 
lysosomal degradation can also be transferred intracellularly onto MHC-I thereby enabling the 
priming of cytotoxic CD8+ cells (Figure 5) [34]. This process is important for the detection of 
tumor antigens and of viruses, which do not infect APCs. IgG-coated antigens can recruit and 
initiate the complement cascade leading to the destruction of the pathogen, a process known 
as complement-dependent cytotoxicity (CDC). These antibody-mediated immune reactions 
are summarized in Figure 5. 
 
Figure 5. Antibody-mediated immune reactions. Antibody-mediated destruction of tumor 
cells depends on the binding of IgG coated with antigens or malignant cells to FcγR expressed 
on NK cells, macrophages and neutrophils (ADCC and phagocytosis processes). Lysosomal 
degradation of cells leads to the release of peptides which can be loaded onto MHC-II and 
activate CD4+ T cells. DCs can also cross-present peptide antigens on MHC-I molecules and 
prime CD8+ T cells. IgG-coated tumor cells can recruit C1q (a complement component), 
initiating the complement cascade and leading to the destruction of the tumor cell by the 
membrane attack complex (MAC). ADCC: antibody-dependent cell cytotoxicity, CDC: 
complement-dependent cytotoxicity. Adapted from [33]. 
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f) Antibodies and pharmaceutical applications 
In 1975, Köhler and Milstein described the production of immortalized B cells, termed 
hybridomas, by the fusion of B lymphoblasts with myeloma cells able to consistently produce 
monoclonal antibodies (mAbs)  against defined antigens [35, 36]. Briefly, a host animal (often 
rodents) is immunized two to three times with the target antigen mixed with an adjuvant in 
order to properly activate the immune system and generate memory B cells. The antigen is 
recognized as ‘foreign’ by the host immune system. During this process B cell activation 
takes place and differentiation into plasmablasts ensures the production of antigen-specific 
antibodies. The spleen of the host is then used as the source of B cells and is fused with 
myeloma cells leading to the formation of hybridomas, which can be selected in a 
hypoxanthine, aminopterin, thymidine (HAT) media. The initial collection of hybridoma cells 
is a heterogeneous pool of polyclonal antibodies. A screening and dilution process is therefore 
needed in order to select for a hybridoma producing the monoclonal antibody of interest. 
Despite of the elegance of this approach, some limitations regarding immunogenicity have to 
be overcome for the development of such antibodies as pharmaceutical drugs. Indeed, the 
administration of a therapeutic antibody produced from rodents leads to the production of  
anti-drug antibodies in humans [37]. Different strategies were pursued in order to decrease 
immunogenicity of rodent-derived antibodies. For example, chimeric antibodies combine the 
variable antigen-binding domains from rodents with a human constant domains [38]. Shortly 
after, new engineering strategies were developed to further humanize the antibodies by 
engrafting the CDRs of the parental antibody into the sequence of a fully human antibody 
[39]. After the introduction of such CDR-grafted, also called humanized mAbs, new 
technologies have been developed in order to produce fully human mAbs. The generation of 
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human antibody libraries enabled the in vitro selection of monoclonal antibodies by for 
example phage or yeast display [40-42]. The repertoire expressed by these phage display 
libraries exceeding the natural B cell repertoire in terms of diversity and affinity maturation 
can be achieved in vitro by means of random PCR-based mutagenesis. In 1994, genetically 
engineered mice expressing fully human antibody repertoires were reported [43]. 
 
Figure 6. Engineering of monoclonal antibodies. The first antibodies were generated using 
the hybridoma technology obtaining a full mouse monoclonal antibody (mAb; in blue). The 
cloning of mouse variable genes into human (in red) constant-region results in chimeric 
antibodies with reduced immunogenicity, which is even lower for CDR-grafted humanized 
antibodies and virtually inexistent when fully human antibodies are used. Adapted from [32]. 
The technological advances in antibody generation platforms are reflected by the more than 
30 mAbs, which have been approved during the last 30 years to treat various diseases. 
‘Blockbuster’ antibodies such as rituximab, infliximab, trastuzumab and cetuximab directed 
against CD20, TNF, human epidermal growth factor receptor 2 (HER2) and epidermal growth 
factor receptor (EGFR), respectively, showed the commercial success of antibodies by 
generating more than one billion revenue annually. Antibody function and production have 
been further developed, leading to a second and third generation of molecules such as 
bispecific antibodies allowing simultaneous binding to two different antigens. Furthermore, 
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highly potent cytotoxic agents have been conjugated to cancer-directed mAbs resulting in 
antibody-drug conjugates [44]. Moreover, omitting the Fc part and its effector functions might 
be an alternative when Fc interactions with immune cells lead to toxic effects (e.g. cytokine 
release syndrome). Additionally, having a reduced molecular size facilitates the penetration 
into solid tumors while a shorter half-life may ameliorate systemic target-dependent toxicity. 
These insights led to the development of different genetically engineered antibody fragments 
such as single chain variable fragments (scFv), diabodies or minibodies (Figure 7). The 
advantage of bivalent diabodies and minibodies is that the avidity of a full mAb is conserved 
while scFv molecules possess only one binding site. Antibody fragments can also be obtained 
by enzymatic digestion using papain or pepsin of a full IgG, resulting in Fab fragments 
(heterodimers of VH-CH1 and VL-CL) and their bivalent equivalents F(ab’)2 respectively, 
where the hinge region remains intact to the CH1 domains connected via disulfide bonds 
(Figure 7). 
 
Figure 7. Antibody-derived fragments. Using enzymatic digestion or genetic engineering 
antibody fragments can be generated avoiding their Fc effector functions. These include 
monovalent and bivalent antibody fragments, whereby bivalent formats predominate in 
therapeutic applications. Adapted from [45]. 
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2. Interleukin-2  
Cytokines are secreted or membrane-bound proteins such as interleukins, interferons, 
mesenchymal growth factors, chemokines and tumor necrosis factor family members. These 
particular proteins regulate the growth, differentiation and activation of immune cells by 
allowing the cells to communicate with each other. Cytokines can have pro-inflammatory (as 
in the case of IL-1, TNF, and IFN-γ) or anti-inflammatory effects (as for IL-4, IL-13, and 
IFN-α). Cytokine receptors can be homodimeric, heterodimeric or their ligands can act as 
trimers assembled then in homotrimeric structures (TNF receptor family).  A subunit of the 
heterodimeric receptors can be shared by different cytokines. This is the case of the common 
gamma chain (γc) cytokines, comprising IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. These 
cytokines bind to receptors comprising the γc subunit and unique cytokine-specific subunits 
[46]. Upon binding to their receptors, one or several signal pathways will be activated (Figure 
8). Cytokines are essential drivers in the development of a variety of diseases such as 
rheumatoid arthritis and psoriasis. In the last years many efforts have been pursued to develop 
antibodies to block pro-inflammatory cytokines or their receptors, such as TNF, IL-6, and IL-
17A [47-49]. Moreover, cytokines have also been developed as recombinant proteins in order 
to use their immune stimulatory activity and treat diseases such as metastatic melanoma, 
metastatic renal cell carcinoma, chronic granulomatous disease, soft tissue sarcoma, and 
multiple sclerosis, where cytokines, including IL-2, IFN-γ, TNF-α, and IFN-β, have shown 
some therapeutic promise [50-53]. The next chapters focus on IL-2, and its relevance for the 
treatment of advanced cancer. 
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Figure 8. Common gamma chain cytokines and their receptors. Shown are receptors for 
IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. The common gamma chain subunit will active Janus 
kinase 3 (JAK3), while the cytokine-specific subunit will activate JAK1. The main signal 
transducer and activator of transcription (STAT) proteins that are activated by their respective 
cytokine receptors are shown in bold. Adapted from [46]. 
a) Biology of IL-2 
Parts of this chapter have been adapted from previously published articles [54, 55]. 
Interleukin-2 (IL-2) is a 15.5-16 kDa four-α-helix bundle cytokine. As a member of the γc 
cytokines, it binds to a monomeric (IL-2Rα or CD25), dimeric (IL-2Rβ or CD122 and γc or 
CD132) or trimeric receptors (CD25, CD122 and γc), which initiate different downstream 
signaling cascades [56, 57]. A crystal structure, showing the special organization of IL-2 with 
its heterotrimeric receptor is shown in Figure 9. 
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Figure 9. IL-2/IL-2 receptor complex. Shown is a ribbon representation of IL-2 (cyan) 
bound to its receptor subunits CD25 (pink), CD122 (orange) and γc (purple). Accession code 
PDB: 2B5I. From [55]. 
CD25 is not involved in IL-2 signaling but increases the affinity of IL-2 towards CD122 and 
γc by about 10 to 100 fold. Signaling is mediated by CD122 and γc. We can therefore 
discriminate between low-affinity (Kd~10-9 M) dimeric and high-affinity (Kd~10-11 M) 
trimeric IL-2 receptors [58]. Dimeric IL-2Rs are found at very high levels on antigen-
experienced (memory) CD8+ T cells and NK cells. Intermediate levels of the dimeric receptor 
can also be found on naïve CD8+ T and memory CD4+ T cells and at lower levels on naive 
CD4+ T cells [56]. Furthermore, activated B cells express the trimeric IL-2Rs [59]. ILCs and 
some non-immune cells, such as endothelial cells, have been reported to express low levels of 
the trimeric IL-2R [60, 61]. Interestingly, DCs have been reported to express CD25 and to use 
it to present IL-2 in trans to T cells expressing dimeric IL-2R [62]. However, the low affinity 
of CD25 to IL-2 questions the biological relevance of such mechanism. When IL-2 binds to 
an IL-2R, the cytokine and receptor subunits are internalized. While IL-2, CD122 and γc are 
degraded, CD25 can be recycled to the cell surface [57]. Upon binding, a signaling pathway is 
initiated involving Janus kinase (JAK)-signal transducer and activator of transcription 
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(STAT), phosphoinositide 3-kinase (PI3K)-AKT and mitogen-activated protein kinase 
(MAPK) (Figure 10) [55, 56, 63].  
 
Figure 10. IL-2 receptor (IL-2R) binding and signaling. Shown are IL-2 interactions with 
CD25, CD122 and γc receptor subunits (left panel). When IL-2 binds to the dimeric IL-2R 
(right panel) heterodimerization of the cytoplasmic tails initiates the activation and 
phosphorylation of Januse kinase 1 (JAK1) and JAK3 leading to subsequent recruitment, 
phosphorylation and activation of the adaptor protein Shc, phosphoinositide 3-kinase and 
signal transducer and activator of transcription 5 (STAT5) pathways whose products undergo 
nuclear translocation and bind to genes responsible for cell activation, differentiation and 
proliferation. Adapted from [55]. 
IL-2 is continuously produced by resting CD4+ T cells. Upon immune activation, cells such as 
NK, NKT, DCs and mast cells are also able to produce IL-2 but at levels that are lower 
compared to the amount produced by activated CD4+ and CD8+ T cells [63]. These activated 
T cells secrete IL-2 which can lead to autocrine and paracrine signaling events. The 
production of IL-2 is also regulated by a negative feedback loop depending on the activation 
levels of STAT-5 and the transcription factor B-lymphocytes-induced maturation protein 1 
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(Blimp1), leading to the suppression of the IL-2 gene (Figure 10) [63]. IL-2 production is 
further regulated at a cellular level involving an equilibrium between IL-2-producing CD4+ T 
cells and IL-2-consuming regulatory T (Treg) cells. Treg cells are unable to secrete IL-2, 
while expressing the high-affinity trimeric IL-2R, and they maintain peripheral immune 
tolerance by dampening effector T cells [64]. IL-2 is crucial for the homeostatic levels of 
thymus-derived Treg cells [65, 66], while ‘induced’ Treg cells (peripherally derived) are able 
to re-differentiate into T h cells and produce IL-2 [67]. Upon IL-2 binding and subsequent 
signaling on Treg cells, CD25 and FoxP3 are further upregulated promoting the suppressive 
capacity of Treg cells [56]. The strength and duration of IL-2 signals control CD4+ and CD8+ 
T cell fates. Upon TCR stimulation, IL-2 production is increased leading to terminal 
differentiation (followed by CD25 upregulation) of both CD4+ and CD8+ T cell subsets into 
short-lived effector T cells. Lower IL-2 signals promote CD4+ T cell differentiation into long-
lived T fh cells or central memory T cells (Figure 11) [56]. 
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Figure 11. IL-2 production and regulatory functions. IL-2 is secreted (as indicated by blue 
arrows) mainly by CD4+ T cells and to a lower extent by CD8+ T, natural killer (NK), and 
NKT cells. IL-2 can bind to and be consumed (red arrows) by cells expressing the dimeric 
low-affinity IL-2 receptor, such as cytotoxic CD8+ T cells and NK cells, or the trimeric high-
affinity receptor present at steady-state conditions on CD4+ Foxp3+ regulatory T (Treg) cells 
and, upon antigen-mediated stimulation, on activated CD4+ (CD4+act) and CD8
+ (CD8+act) T 
cells. 
b) Clinical relevance and applications of IL-2 
As previously described, IL-2 is essential for the homeostasis and suppressive activity of Treg 
cells and for efficient stimulation of cytotoxic T cells. In order to maintain immune tolerance 
and immunity, a balance between these subsets has to be in place. The consequences of IL-2 
and CD25 deficiencies are well reflected in mice [63] and humans [68, 69] developing 
autoimmune and/or inflammatory reactions with a higher susceptibility for certain infections. 
A complete lack of IL-2 or CD25 is rare in humans but partial deficiencies have been linked 
to several pathologies such as type 1diabetes, multiple sclerosis and rheumatoid arthritis [70, 
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71]. This resulted in the implementation of clinical trials using low-dose IL-2 in order to 
promote Treg cell function. Efforts to treat type 1 diabetes [72, 73], autoimmune vasculitis 
[74] and chronic graft-versus-host-disease [56, 75] led in a subset of patients to clinical 
improvements [76]. Moreover, the technical difficulties encountered with the isolation, 
expansion and reinfusion of Treg cells favors IL-2 low-dose administration (500 000-3 000 
000 international units (IU) or 15 000-30 000 IU once daily in humans and mice, 
respectively). On the other hand, administration of IL-2 at higher doses (600 000-720 000 
IU/Kg body weight three times daily for up to 14 doses per cycle in humans or 100 000 IU or 
higher once or twice daily in mice) stimulate cells expressing the dimeric IL-2R such as CD8+ 
T cells and NK cells once Treg cells have been saturated with IL-2. Such high-dose IL-2 
immunotherapy is used for the treatment of certain metastatic cancers [77]. After successful 
pre-clinical studies in various murine tumor models, high-dose IL-2 has been approved by the 
Food and Drug Administration (FDA) in humans for the treatment of metastatic renal cell 
carcinoma in 1992 and metastatic melanoma in 1998. This led to a 15-19% objective clinical 
response (with 7-9% complete response) in patients [78].  
3. Cancer immunotherapy 
a) A brief introduction to cancer 
Healthy tissues are composed of cells that control the production and release of growth 
signals in order to maintain a homeostatic level and ensure tissue composition and function. 
Some cells, by deregulating those homeostatic signals can start a proliferative program 
resulting in uncontrolled cell growth. The interaction between external carcinogenic agents 
such as ultraviolet, ionizing radiation, chemical carcinogens (e.g. components of tobacco, 
aflatoxin), or biological carcinogens (e.g. human papillomavirus) with genetic factors drive 
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this deregulation, resulting in malignant cell growth, which ultimately can lead to the invasion 
of surrounding tissues by the cancer and metastasize to distant sites. A lot of efforts went into 
understanding how cancer cells could proliferate in such manner. In 2000, Hanahan and 
Weinberg proposed six hallmarks of cancer, including distinctive and complementary 
capabilities enabling tumor growth and metastatic formation [79]. Cancer cells do not need 
growth signals in order to proliferate and they become insensitive to extrinsic and/or intrinsic 
processes preventing their own division. Their survival is also linked to their capacity to 
evade programmed cell death, their limitless replicative potential and their sustained 
angiogenesis (blood vessels formation), allowing them to spread and invade surrounding 
tissues. The complexity and diversity of solid tumors and haematologic malignancies has led 
to an extended set of ten cancer hallmarks in 2010 by the same authors (Figure 12) [80]. A 
better understanding of the biology of tumor development has led to the generation of 
therapeutics targeting pathways of almost all hallmarks of cancer.  
 
Figure 12. The updated hallmarks of cancer and corresponding therapeutic approaches. 
From [80]. 
 33 
 
b) Anti-cancer immunity 
The term ‘cancer immunotherapy’ appeared for the first time in 1891, when William Coley 
began to study intratumoral injections of live inactivated Streptococcus pyogenes and Serratia 
marcescens, later called Coley’s toxins, and observed complete tumor remission of sarcomas 
in patients [81]. Assuming that the immune system is able to cause inflammation and destroy 
pathogens as previously described, the theory of William Coley could be explained by the 
activation of the immune system through the stimulation of antibacterial phagocytes that 
could also attack tumor cells. Although a certain efficacy was observed, results were difficult 
to reproduce and the risk associated with the administration of infectious agents led 
oncologists to rely on surgery and effective methods such as radiation therapy and 
chemotherapy. In the early 1900s, Paul Ehrlich suggested that immune cells may hold 
cancerogenic cells in check but it took over 50 years until the first demonstration of the 
existence of tumor antigens [82], which can be recognized by immune cells. In the past two 
decades, extensive efforts were taken to understand how cancer evades the immune system 
and how this process can be prevented or reversed. This led to studies postulating the cancer 
immunosurveillance hypothesis where adaptive immunity is thought to prevent cancer 
progression in healthy hosts. Follow-up studies by Stutman and colleagues did not support 
this theory, leading to a controversy about the term cancer immunity. The development of 
immunodeficient mouse models on defined genetic backgrounds gave the basis to further 
investigate the role of the immune system in cancer development. Mice lacking 
responsiveness to IFN-γ or components of adaptive immunity developed faster tumors 
showing the relevance of immune-mediated tumor control [83]. Since then a large number of 
research studies contributed to the understanding of the steps needed to get an effective anti-
 34 
 
tumor immune response, including the stimulation of innate immune recognition promoting 
antigen-presentation therefore leading to the generation of protective T cell responses which 
have the capacity to overcome immunosuppression at the tumor site. DCs have to take up and 
cross-present antigens derived from tumors. DCs receiving sufficient co-stimulation are then 
able to migrate to lymph nodes to properly mount an immune response. In a last step, primed 
Tc and/or NK cells need to migrate to the tumor site where they exert their cytotoxic function 
and thereby eliminate tumor cells (Figure 13).  
 
Figure 13. The generation and regulation of anti-tumor immune responses. Adapted from 
[84]. 
c) Cancer vaccines 
In the late 1980s, the capacity to obtain cytotoxic T lymphocytes from patients with 
melanoma unable to act against normal cells but against cells expressing mutated proteins 
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allowed the identification of different tumor antigens [85]. Those antigens can be different for 
a given type of cancer and may result from mutations which occurred during the 
transformation of normal cells into malignant cells. Other tumor antigens can be products of 
genes preferentially expressed by cancer cells such as cancer-testis antigens [86-89], 
differentiation antigens against which peripheral or thymic tolerance has not been completely 
established, or antigens associated with the tissue where the cancer originates from such as 
melanocyte-specific antigens [90-92]. Based on these findings therapeutic vaccination 
strategies were developed, relying on the systemic administration of tumor antigens. 
However, these therapeutic approaches showed only limited efficacy in the clinics [93]. A 
possible explanation may be that DC maturation relies on optimal activation through 
endogenous signals (such as necrotic tumor cells releasing factors), co-stimulatory molecules 
(such as CD40L) or cytokines. These signals, like TLR ligands or agonistic antibodies 
activating receptors such as CD40, are also called adjuvants when administered to a patient or 
animal [94].  
When a cancer is of viral origin, such as cervical cancer mainly caused by infection with the 
human papillomavirus (HPV), a prophylactic vaccine can be used to prevent the formation of 
HPV-induced malignant cells. The development of therapeutic vaccines has been tested and 
improved in the last years. The idea behind this approach is the administration of peptides 
known to be recognized as ‘foreign’ and supposedly expressed by tumor cells, in combination 
with adjuvants in order to activate DCs that will engulf and present the peptide on MHC-I 
molecules to then activate Tc cells. One example was the use of peptides derived from the 
HPV-16 E6 and E7 oncoproteins administered in incomplete Freund’s adjuvant to women 
with vulvar intraepithelial neoplasia. Tumor regressions in 15 of 19 women were correlating 
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with the generation CD8+ and CD4+ T cells secreting large amounts of IFN-γ and being 
specific for the HPV oncoproteins [95]. The property of virus to elucidate strong immune 
responses is currently exploited in order to develop vaccines where tumor antigens will be 
encoded by viral vectors [96]. Moreover, a particular interest in developing DC-based 
vaccines has emerged. The specialized APCs are isolated from cancer patients, ex vivo 
stimulated with peptides and re-infused back to patients [97]. In order to break self-tolerance, 
the immunogenicity of peptides has to be above a certain threshold as shown by the p53 
vaccine leading to only weak T cell response [98]. This is why full length proteins are being 
investigated as targets for cancer vaccinations [99]. Cancer vaccines represent a powerful tool 
for tumor immunotherapy but a lot of limitations need to be overcome such as optimal tumor 
target and adjuvant in order to induce strong anti-tumor T cell responses with the capacity to 
overcome tumor-induced immune suppression. 
d)  Adoptive cell therapy 
The adoptive transfer of autologous, in vitro expanded tumor-infiltrating lymphocytes (TILs), 
termed adoptive cell therapy (ACT), has shown durable clinical responses in 50% of patients 
with melanoma [100]. The efforts in T cell engineering opened further perspectives in ACT. 
One example was the development of chimeric antigen receptor (CAR) T cell therapy, which 
relies on genetically modified T cells expressing an antigen-binding domain (e.g. a scFv) on 
their surface which mimics a tumor antigen-specific TCR [101].  
e) Antibody therapy of cancer 
The use of mAbs for cancer therapy has been successfully developed in the last several years 
[33]. They can target tumor antigens and kill tumor cells either by induction of apoptosis 
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[102], the delivery of cytotoxic agents (antibody drug conjugates) or immune-mediated cell 
killing mechanisms such as ADCC or CDC (see also Figure 5) [103].  
As previously discussed, the specificity of T cells for tumor cells is mediated by the 
interaction of their TCR with an MHC molecule displaying the processed tumor antigen on 
the cell surface. However, T cell activation also relies on the engagement of co-regulatory 
receptors expressed on the surface of T cells binding to cognate ligands displayed on APCs or 
tumor cells. The discovery and study of these co-stimulatory or co-inhibitory receptors 
provided a number of potential targets for the development of agonist antibodies directed 
against 4-1BB, OX40, CD27 and CD28. Notably, agonist mAbs directed to CD28 resulted in 
unexpectedly life-threatening conditions of patients in early clinical trials resulting from rapid 
release of cytokines by activated T cells [104]. These events have shown the power of our 
immune system and the necessity to tightly control it. Other approaches, which were far more 
clinically successful due to better therapeutic windows and side-effect profiles, are targeting 
immunosuppressive co-inhibitory molecules [105] with antagonist antibodies directed against 
LAG-3, CTLA-4 [106] and PD-1 [107, 108] (Figure 14).  
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Figure 14. Activating and inhibitory receptors on T cells. T cell receptors transmit 
stimulatory or inhibitory signals upon binding to their ligands, which can be expressed by 
APCs or tumor cells. Such molecules represent targets for antibody-mediated cancer 
immunotherapy. Adapted from [84]. 
The potential of blocking CTLA-4 was first demonstrated in 1996 and provided the basis for 
the development of two fully human mAbs: ipilimumab and tremelimumab. Clinical trials in 
patients were successful leading to an increased survival in patients with metastatic 
melanoma. Side effects related to tissue-specific inflammatory responses were observed in 
patients, but could be controlled without affecting the efficacy of the therapy [106]. The 
success of these inhibitory TCR blockers, commonly referred to as immunological check 
point inhibitors, led to the development of fully human mAbs blocking PD-1. These mAbs, 
namely nivolumab and pembrolizumab, showed promising responses in patients with 
melanoma, renal cell carcinoma, non-small-cell lung cancer, and colorectal cancer [107]. It 
will be important to follow-up the treated patients in order to know whether the responses will 
be durable and which side effects will come along with the therapy. A summary of antibody 
therapeutics approved for use in oncology is provided in  
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Antibody Engineering Isotype Target 
FDA approved indication 
year 
Bevacizumab 
Humanized IgG1 
VEGF-
A 
Colorectal/lung cancer 
(Avastin®) 2004 
Cetuximab 
(Erbitux®) 
Chimeric 
Murine/Human 
IgG1 
EGF 
receptor 
(EGFR) 
Colorectal cancer 
2004 
Panitumumab 
(Vectibix®) 
Human IgG2 EGFR 
Colorectal cancer 
2006 
Ipilimumab 
(Yervoy®) 
Human IgG1 
CTLA-
4 
Metastatic melanoma 
2011 
Pembrolizumab 
Humanized IgG4 PD-1 
Metastatic melanoma 
(Keytruda®) 2014 
Nivolumab 
(Opdivo®) 
Human IgG4 PD-1 
Metastatic melanoma 
2014 
 
Table 2. 
Antibody Engineering Isotype Target 
FDA approved indication 
year 
Rituximab 
(Rituxan®) 
Chimeric 
Murine/Human 
IgG1 CD20 
Lymphoma 
1997 
Trastuzumab 
(Herceptin®) 
Humanized IgG1 HER2 
Breast cancer 
1998 
Alemtuzumab 
Humanized IgG1 CD52 
Chronic lymphocytic 
leukemia 
(Campath®) 2001 
Ofatumumab 
(Arzerra®) 
Human IgG1 CD20 
Lymphoma 
2009 
Pertuzumab 
Humanized IgG1 HER2 
Breast cancer 
(Perjeta®) 2012 
Obinutuzumab  Humanized-
glycoengineered 
IgG1 HER2 
Breast cancer 
(Gazyva®) 2013 
 
Table 1a. Unconjugated monoclonal antibodies approved for the treatment of cancer 
targeting cancer cells. Adapted from [33, 109, 110]. 
Antibody Engineering Isotype Target FDA approved indication 
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year 
Bevacizumab 
Humanized IgG1 
VEGF-
A 
Colorectal/lung cancer 
(Avastin®) 2004 
Cetuximab 
(Erbitux®) 
Chimeric 
Murine/Human 
IgG1 
EGF 
receptor 
(EGFR) 
Colorectal cancer 
2004 
Panitumumab 
(Vectibix®) 
Human IgG2 EGFR 
Colorectal cancer 
2006 
Ipilimumab 
(Yervoy®) 
Human IgG1 
CTLA-
4 
Metastatic melanoma 
2011 
Pembrolizumab 
Humanized IgG4 PD-1 
Metastatic melanoma 
(Keytruda®) 2014 
Nivolumab 
(Opdivo®) 
Human IgG4 PD-1 
Metastatic melanoma 
2014 
 
Table 2b. Unconjugated monoclonal antibodies approved for the treatment of cancer 
having a different mode of action. Adapted from [33, 109, 110]. 
Moreover, the efforts in antibody engineering led to new therapeutic applications. Notably, 
bispecific molecules targeting tumor antigen and the TCR-associated CD3 have the ability to 
bring tumor cell and the Tc in close proximity, which enables efficient Tc-mediated tumor 
cell killing [111]. Other approaches to overcome tumor-induced immunosuppression include 
targeting immunosuppressive cells such as Treg or myeloid-derived suppressor cells, found at 
higher counts in the tumor site [112]. These cells release immunosuppressive cytokines such 
as IL-10, TGF-β, arginase 1 and 2, and nitric oxide synthase 2 (NOS2), which block Tc 
proliferation and induce apoptosis of these cells. 
There are different tumor escape mechanisms to antibody treatment including the 
heterogeneous level of tumor antigen expression and the biophysical properties of antibodies 
(such as size and half-life) influencing their ability to access the intratumoral 
microenvironment. Immune escape mechanism such as ineffective FcγR binding and immune 
suppression can lead to poor clinical responses [113]. Moreover, the ability of antibodies to 
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generate T cell responses towards tumor antigens depends on various factors, such as antigen 
cross-presentation by DCs and immune escape mechanism mediated by Treg cells and 
myeloid derived suppressor cells (MDSCs) [114].  
f) Immunotherapy using cytokines 
Various cytokines are produced in the tumor microenvironment and play an essential role 
during cancer progression or control. The role of some of these molecular messengers in 
tumor formation and development has been elucidated using immunodeficient mice. For 
example, IFN-γ inhibits chemical carcinogenesis and lymphoma development [115, 116], 
granulocyte-macrophage-colony stimulating-factor (GM-CSF) inhibits lymphomas and 
carcinomas in combination with IFN-γ [117]. By contrast, other pro-inflammatory cytokines 
such IL-1 can promote tumor invasion and angiogenesis [118]. The study of the cytokine 
microenvironment has led to their therapeutic use for cancer treatment. Systemic IL-12 has 
shown strong anti-tumor effect in mice, but clinical trials have been stopped due to toxicity 
[119]. Recombinant IFN-α has been shown to potentiate the anti-tumor response in various 
cancers [120] and GM-CSF has proven some benefit in melanoma and prostate cancer [121, 
122].  As previously mentioned, IL-2 has been used for treatment of metastatic melanoma and 
metastatic renal cell carcinoma. Its therapeutic application plays a pivotal role for the 
treatment of patients with metastatic melanoma resistant to cytotoxic chemotherapy [123]. 
However, also this treatment is limited by the IL-2-related side effects and the short half-life 
of the cytokine itself, as IL-2 is rapidly cleared via the kidneys (3 to 5 minutes in mice and 7 
to 10 minutes in humans) [124, 125]. The side effects have been linked to an indirect NK cell-
mediated mechanism involving the release of vasoactive mediators, such as TNF-α, as well as 
to CD25-dependent endothelial cell damage induced by the binding of IL-2 to the endothelial 
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surface receptors leading to the vascular leak syndrome (VLS) [56, 60]. One line of research 
aims to improve the clinical application of IL-2 by e.g. incorporating IL-2 in fusion proteins 
aiming to target the cytokine to the tumor site [126-128]. The drawback of such applications 
is the simultaneous expansion of Treg cells, which could suppress the effect of the activated 
Tcs [129, 130]. Of note, IL-15-based immunotherapy is also under investigation. It differs 
from IL-2 in terms of receptor binding; IL-15 has a high affinity for its IL-15 receptor α 
subunit and causes therefore lower CD25-mediated cytotoxicity. This has led to the 
development of molecules where IL-15 has been fused to its soluble receptor IL-15Rα 
showing better tumor control in mouse models [131, 132].  
g) Improved IL-2 immunotherapy using IL-2cx 
IL-2 can bind and stimulate CD8+ T cells and NK cells expressing the dimeric IL-2R 
(CD122high cells) but also Treg cells expressing the trimeric IL-2R. Using specific anti-IL-2 
mAbs, which bind IL-2 and form so-called IL-2/mAb complexes (IL-2cx), IL-2 can be 
preferentially directed to CD122high or CD25high cells. This selectivity has been previously 
demonstrated in animals receiving IL-2cx or IL-2 alone [60, 133, 134]. Five to seven daily 
injections of mouse IL-2 (mIL-2) complexed with an anti-mIL-2 (mAb clone S4B6 or S4B6 
like antibodies) led to the expansion of CD122high cells by 20-40 fold versus a 2 to 5 fold 
expansion of Treg cells. In line with this finding, lower mIL-2 doses (15 000 IU when 
complexed with mAb) are needed compared to mIL-2 alone (200’000 IU) in order to get 
preferential stimulation, leading to significantly reduce IL-2-related side effects correlating 
with less binding to CD25+ endothelial cells [60, 133]. The therapeutic outcome of IL-2/S4B6 
complexes are in line with the recent structural data showing that S4B6 associates and inhibits 
the CD25 binding epitope of mIL-2 [55, 135]. On the other hand, when mIL-2 is complexed 
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with a specific mAb such as clone JES6-1A12, three to seven daily injections increases Treg 
cell numbers by 7 to 15 fold compared to mIL-2 alone (Figure 15) [133, 134, 136]. When IL-
2 is complexed to a mAb the half-life of IL-2 is increased by 10 to 20 fold [133, 137]. The 
increased half-life is mediated by neonatal Fc receptors but, interestingly, FcγR do not seem 
to play an important role on the observed in vivo effects of IL-2-cx [133, 137]. Until to date, 
mIL-2/S4B6 complexes have been tested in various tumor and acute and chronic infection 
models showing their pre-clinical efficacy [60, 138, 139].  
 
Figure 15. T cell subtype-specific receptor interactions of IL-2cx. IL-2/S4B6 complexes 
(blue) preferentially stimulate CD122high cells including memory CD8+ T cells (green) and 
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NK cells (not shown). On the other hand, IL-2/JES6-1 complexes (red) only stimulate 
CD25high cells such as Treg cells (brown). From [55]. 
h) IL-2 muteins 
Another approach to increase IL-2 efficacy and/or reduce its associated side effect is the 
generation of IL-2 mutants, or so-called IL-2 muteins. The first mutational studies were done 
in order to decrease IL-2’s affinity for CD122. The idea behind goal was to limit NK cell 
activation and release of TNF-α, which were thought to be the central players of vasodilation 
and therefore VLS at that time. However, the developed N88R (BAY50-4798) and the D20T 
mutants of IL-2 (Selectikine) did not show lower toxicity levels in clinical applications [54, 
140, 141]. The decreased side effects observed with IL-2/S4B6 complexes disfavoring the 
stimulation of CD25+ cells (including endothelial cells) and preferentially expanding 
CD122high cells led to the development of the next generation of IL-2 muteins. These IL-2 
mutants (H9 or D10) being modified on amino acids 80 to 92, showed that the substitutions 
L80F, L85V and I86V were essential in order to get 200 fold higher affinity for CD122, better 
tumor control and less side effects compared to IL-2 alone [142]. An alternative approach was 
to generate an IL-2 mutein with lower affinity for CD25. The resulting IL-2 mutant, the so-
called ‘no-α-muteins’, displayed superior tumor control and reduced side effects when 
compared to IL-2 alone. Another mutant termed F42A, also having a decreased affinity for 
CD25 performed similarly in vivo [54, 142, 143].  
i) Combination therapy 
The success of cancer immunotherapy depends on a coordinated recruitment of innate and 
adaptive immunity, including soluble and cellular factors. In such a case, the tumor cells can 
be destroyed before becoming invasive. However, some tumor cells can survive and enter an 
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equilibrium phase, as postulated in 2011 by Schreiber and colleagues and termed ‘The cancer 
immunoediting concept’ [83]. At this stage, an adaptive immune response is needed in order 
to prevent uncontrolled tumor growth and metastasis. Unfortunately, as a consequence of 
immune selection pressure some tumor cells may not be any more recognized as foreign by 
loss of antigenicity and/or develop resistance to cellular cytotoxicity [144, 145]. 
Simultaneously, tumor cells may induce and maintain an immunosuppressive environment 
allowing them to escape and grow in an uncontrolled manner. In order to prevent such 
immune evasion, a strategy targeting different effector arms of the immune system using 
combinatorial approaches is of great clinical interest [146]. Various pre-clinical models have 
shown the benefit of therapy combinations like the administration of anti-CTLA-4 or anti-PD-
1 in combination with vaccines leading to better tumor control [147, 148]. Moreover, the 
synergy observed with combinatorial CTLA-4 and PD-1 blockade in animals prompted the 
clinical testing of this combination [149]. However, such combinations need to be properly 
tested in order to limit additive immune-mediated toxicities [150].  
4. Epigenetic modulation of tumor control 
Conrad Waddington introduced the term epigenetics in the early 1940 [151]. It refers to the 
molecular pathways modulating the expression of genes that are not due to any alteration in 
the DNA sequence. The mechanisms involved in epigenetic gene regulation include 
methylation of cytosines in DNA and enzymatic modification state of histones. Several 
enzymes are known to be involved in mediating post-translational histone modifications such 
as methylation or deacetylation. Acetylation of histone (H) lysines (K) is generally associated 
with transcriptional activation while the consequence of histones methylation depends on the 
residue and the site of methylation [152]. For example, methylation of H3 at K4 is linked to 
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transcriptional activation [153] but methylation of H3 at K9 or K27 leads to transcriptional 
repression. Low levels of DNA methylation have been found in human cancer tissues [154]. 
Moreover, hypermethlyation of DNA regions containing many adjacent cytosine and guanine 
nucleotides (referred as ‘CpG islands’) in the promoter regions of tumor suppressors regions, 
have been found in many types of cancers [155-157]. The hypermethylation state of genes 
closely depends on histone modifications. The enhancer of zeste homologue 2 (EZH2) makes 
part of the multiprotein polycomb repressive complex 2 (PRC2, Figure 16). EZH2 is a highly 
conserved histone methyltransferase found to be overexpressed in many cancers such as 
melanoma and breast cancer [158-160]. It mediates the tri-methylation of lysine 27 on histone 
3 (H3K27me3), thus inducing chromatin compaction and leading to transcriptional repression 
of target genes (Figure 16) [160-162]. EZH2 is essential in early development but it is 
downregulated in normal adult tissues [163]. High EZH2 levels have been linked to a stem 
cell-like state in cancer by repressing genes involved in differentiation while allowing 
expression of genes involved in cell division [164].  
 
Figure 16. Multiprotein polycomb repressive complex 2 (PRC2). Polycomb repressive 
complexes (PRCs) are essential mediators of transcriptional repression. In PRC2 the co-
factors SUZ12 and EED interact with nucleosomes and induce EZH2 catalytic activity 
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responsible for trimethylation of  lysine 27 on histone H3, thus leading to transcriptional 
repression. Adapted from [161]. 
Mutations within the catalytic site of EZH2 lead to a permanent tri-methylation state and have 
been identified in 22% of lymphomas [165-167]. Furthermore, high levels of EZH2 have been 
associated with more aggressive forms of melanoma and increased proliferation and invasion 
of cancer cells [168]. Likewise, it has been shown that EZH2 mediates the repression of 
different tumor suppressors and differentiation genes [169]. The key role played by EZH2 in 
malignant melanoma progression was shown in a genetic mouse model of cutaneous 
melanoma [170]. Interestingly, EZH2 overexpression has been linked to inefficient T cells 
immune response in uveal melanoma [171]. Because of its role in cancer, EZH2 has been 
validated as a promising target for the development of small molecule inhibitors. Several 
inhibitors are currently being tested in preclinical and clinical studies. The first drug described 
was the molecule DZNep. It acts through the inhibition of the S-adenosyl homocysteine 
hydrolase causing the degradation of proteins members of the PRC2 complex and leading to 
H3K27 demethylation [172]. Even though the drug has shown some success, its lack of 
specificity led to the development of more selective inhibitors such as GSK126 [166], 
GSK343, and GSK503. In vivo studies of such inhibitors demonstrated the correlation 
between tumor control and decreased levels of H3K27me3 [173]. Within the present thesis, 
we have evaluated the inhibitor GSK503 in combination with human IL-2cx in various 
melanoma models. 
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IV. Aims 
As previously described, IL-2 immunotherapy can be enhanced by delivering IL-2 as IL-2cx, 
which preferentially stimulate CD122high cells. Currently, no monoclonal antibody (mAb) to 
human (h) IL-2 suitable for clinical development in cancer immunotherapy is available. The 
first aim of my thesis was to develop a rational approach to generate an anti-hIL-2 antibody 
acting as CD25 mimic (which we have termed NARA1). The generation is followed by in 
vitro characterization of the antibody allowing us to precisely define the binding epitope on 
hIL-2. Then the in vivo properties of the hIL-2/NARA1 complex (IL-2cx) need to be tested in 
order to check for its specificity (stimulation of CD122high cells) and anti-tumor effects. 
Despite potent and constant stimulation of the immune system using IL-2cx in aggressive 
melanoma models, tumors use several mechanisms (through genetic and/or epigenetic 
alterations) to become resistant to apoptosis or to counterattack the immune system. The 
second aim of my thesis was to the check if IL-2cx immunotherapy would promote epigenetic 
modifications leading to tumor cell dedifferentiation, loss of immunogenicity and immune 
escape. Once we observed a clear correlation between up-regulation of the histone 
methyltransferase enhancer of zeste homologue 2 (Ezh2) and IL-2cx immunotherapy, we aim 
to test and elucidate the mechanisms of the combination therapy consisting of Ezh2 blockade 
and IL-2cx in order to better control tumor growth in vivo. 
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V. Results 
1. Rational generation of CD25-mimobody specific for human IL-2 
Adapted from a manuscript submitted to Science Translational Medicine. 
‘Improved cancer immunotherapy by rational generation of CD25-mimobody 
conferring selectivity to human interleukin-2’ 
Natalia Arenas-Ramirez1, Chao Zou2, Simone Popp2, Catherine Regnier2, Barbara Brannetti2, 
Emmanuelle Wirth2, Thomas Calzascia2, Jiri Kovarik2, Daniel Zingg3, Lukas Sommer3, 
Gerhard Zenke2, Andreas Katopodis2, and Onur Boyman1* 
1 Department of Immunology, University Hospital Zurich, University of Zurich, CH-8091 
Zurich, Switzerland 
2 Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4002 Basel, 
Switzerland 
3 Cell and Developmental Biology, Institute of Anatomy, University of Zurich, CH-8057 
Zurich, Switzerland 
* Corresponding author: onur.boyman@uzh.ch 
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a) Rational based screening for generation of selective anti-human IL-2 antibodies 
We have previously hypothesized that CD122-directed IL-2/antibody complexes are made of 
anti-IL-2 mAbs that occupy IL-2's CD25-binding site [55, 133, 134]. Hence, we established a 
screening approach for such mAbs (fig. S1A). As the affinity of recombinant hCD25 to hIL-2 
is low (Kd ~10
-8 M) and thus unsuitable for use in a sandwich enzyme-linked immunosorbent 
assay (ELISA), we tested various available anti-hIL-2 mAbs, when complexed to hIL-2, for 
their ability to expand either CD25high cells (termed mAbcap) or CD122
high cells (termed 
mAbdet) in vivo. We verified that binding of mAbdet to hIL-2 prevented the binding of hCD25 
to the same hIL-2 molecule. We then used mAbcap and mAbdet as capture and detection 
antibodies, respectively, in a competitive sandwich ELISA to screen newly-generated anti-
hIL-2 mAbs for their ability to prevent mAbdet binding to hIL-2 and to preferentially expand 
CD122high CD8+ T cells and NK1.1+ DX5 (CD49b)+ NK cells in vivo (fig. S1B). About 0.2% 
of all anti-hIL-2 mAbs were efficiently displacing mAbdet, even at low concentrations, and 
showed selective and potent expansion of CD122high lymphocytes in vivo, of which clone 
NARA1 was most promising. 
b)  Structure of hIL-2/NARA1 complex shown analogy of NARA1 to CD25 
We used surface plasmon resonance (SPR), to assess whether binding of hIL-2 to NARA1 
prevented further binding to hCD25. To this end, hIL-2 was loaded on immobilized NARA1 
prior to injection of recombinant hCD25 or hCD122. In this setting, hCD25 was unable to 
bind, even at high concentrations, while hCD122 readily associated with NARA1-bound hIL-
2 (Fig. 1A, and fig. S2A). Conversely, hIL-2 loaded on immobilized mAbcap allowed efficient 
association with hCD25, but not with hCD122 (fig. S2, B and C). The affinity of NARA1 to 
hIL-2 was ~10-9 M, as determined by SPR fitting curves, showing a lower off-rate (fig. S3). 
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Unlike mAbdet, NARA1 showed no cross-reactivity with mouse IL-2 (mIL-2; fig. S4, A and 
B). To gain further insight into the structural and mechanistic properties of NARA1, we 
determined the crystal structure of the hIL-2/NARA1 (Fab) complex to a resolution of 1.95 Å. 
The association of hIL-2 and NARA1 relied mainly on electrostatic interactions (Fig. 1B). In 
comparison to the structure of the quaternary complex of hIL-2 with its trimeric hIL-2R [174, 
175] NARA1 bound hIL-2 'on top', that is dorso-laterally, and at an angle similar to hCD25 
(Fig. 1, C and D). Overlaying the structures of the hIL-2/NARA1 and hIL-2/hIL-2R 
complexes showed that position and angle of NARA1, particularly the VH domain of NARA1, 
closely overlapped with hCD25 (Fig. 1E). 
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Figure 1.  Three-dimensional structure of NARA1/IL-2 complex shows strong analogy of 
NARA1 to CD25. (A) Equilibrium surface plasmon resonance titration of human (h) CD122 
and hCD25 interacting with immobilized NARA1 bound to hIL-2 at saturating concentration. 
Data are representative of three independent experiments. (B) View of electrostatic interaction 
interfaces between hIL-2 and NARA1. (C) Ribbon representation of hIL-2/hIL-2R quaternary 
complex (IL-2, grey; CD25, red; CD122, purple; c, gold; PDB accession code: 2B5I;[174]). 
(D) Overlay of NARA1 on hIL-2/hIL-2R quaternary complex with NARA1 heavy and light 
chains in blue and cyan, respectively. (E) Overlay of NARA1 (surface representation), hIL-2, 
and hCD25. 
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c) IL-2 residues contacting CD25 are involved in binding to NARA1 
Analysis of the interface between hIL-2 and NARA1 revealed that hIL-2 residues P34, K35, 
R38, T41, Q74, and K76 were most prominent in forming the epitope, with R38 being the 
most crucial (Fig. 2, A and B). These residues had the possibility of forming 10 and more 
direct intermolecular contacts with NARA1, as measured by the number of NARA1 atoms 
within 4 Å of hIL-2, and showed reduced solvent-accessible ('buried') surface of 50 Å2 and 
more after binding to NARA1 (Fig. 2A). Significantly, R38 and its neighboring residues 
formed a hot spot comprising a loop and a short -helix connecting helices A and B of hIL-2, 
which contained the most important hIL-2 residues contacting hCD25 (Fig. 2, A and B) [176]. 
Moreover, the residues Q74 and K76 participated in a smaller secondary interaction spot in a 
loop connecting helices B and C, of which L72 has been involved in hCD25 interaction [175, 
176] 
d) NARA1 binding sites differ from S4B6 and mAbdet epitopes on IL-2 
We next compared the hIL-2/NARA1 complex with a recently published structure of a 
CD122-directed mIL-2/anti-mIL-2 (clone S4B6) antibody complex [135]. In the reported 
structure of mIL-2/S4B6 complex, S4B6 occupied part of IL-2's CD25 epitope, leaving R38 
and some other CD25-interacting IL-2 residues unbound [55, 135]. Moreover, unexpectedly, 
S4B6 affected IL-2 binding to CD122 by exerting two seemingly antagonistic effects 
consisting of a slight steric clash between S4B6 and CD122 versus an affinity-enhancing 
structural change of IL-2's CD122-binding loop [55, 135]. The latter is reminiscent of a hIL-2 
mutein (termed 'IL-2 superkine') with increased CD122 binding [142]. In comparison to 
NARA1 associating with hIL-2 mainly via a short -helix stretch connecting helices A and B 
(Fig. 2C), S4B6 bound mIL-2 residues that were located in helices B and C (Fig. 2D, and  
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[135]), consistent with earlier data from S4B6 epitope mapping studies [177]. Consequently, 
NARA1 and S4B6 interacted with mostly unrelated IL-2 epitopes (fig. S5), resulting in 
binding to IL-2 at different angles (Fig. 2E). Moreover, hCD25 fitted nicely into the density 
graph of NARA1, while overlap of S4B6 with hCD25 was notably different, with significant 
parts of CD25 still exposed (Fig. 2E). Interestingly, NARA1-bound hIL-2 adopted the 
allosteric changes in helix C (fig. S6) observed with binding of hIL-2 to hCD25 or described 
for the IL-2 superkines [142, 174], although these changes in hIL-2/NARA1 complex did not 
lead to increased signaling or proliferation of responder cells in vitro (see below). 
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Figure 2.  Key IL-2 residues mediating contact with CD25 are also involved in binding to 
NARA1 antibody. (A) Number of NARA1 (Fab) atoms within 4 Å of hIL-2 indicating direct 
intermolecular contacts (blue bars) and reduced solvent-accessible surface (Å2) of hIL-2 after 
binding to NARA1 (red bars). Numbers in the middle of the graph represent hIL-2 residues, 
with red boxes indicating residues involved in hCD25 binding [55]. (B) Close view of 
NARA1 binding site to hIL-2 with key residues indicated. NARA1 heavy and light chains are 
shown in blue and cyan, respectively. (C–E) Ribbon and surface representation of hIL-2 
(helix A, green; helix B, gold; helix C, dark orange; helix D, pink) with NARA1 (C) or mIL-2 
with S4B6 (D; light chain, lime; heavy chain, light green), and overlay of these complexes 
with hCD25 (red) (E). 
Generation of hIL-2 muteins containing a single amino acid mutation at R38 or F42 revealed 
that R38, but not F42, was essential for binding to NARA1. Conversely, linear peptide 
mapping to identify linear hIL-2 sequences binding to the anti-hIL-2 mAbs did not show any 
significant interaction with NARA1, whereas mAbdet readily bound to hIL-2 linear peptides 
containing amino acids 37 to 42 (Fig. 3A). Accordingly, introduction of an F42A mutation 
abrogated binding to mAbdet, but not to NARA1 (Fig. 3B). These results indicate that NARA1 
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binds to a three-dimensional epitope of hIL-2 that is different from mAbdet and S4B6 and 
contains the most prominent hCD25-interacting residues. 
 
Figure 3.  NARA1 binding sites differ from mAbdet epitopes on IL-2. (A and B) Linear 
peptide mapping of NARA1 and mAbdet binding sites to unmodified hIL-2 (A) or after 
mutation of F42, Y65 and L92 to an alanine residue (B). Shown is the signal intensity for both 
antibodies after subtraction of control signal (AU). Sequences of peptides and residue 
numbers in brackets are provided. Data are representative of two independent experiments. 
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e) hIL-2/NARA1 complex stimulates T cells independently of IL-2R crosslinking 
To assess the functional properties of NARA1, we compared hIL-2 to hIL-2 complexed to 
NARA1 at a 2:1 ratio (hIL-2/NARA1 complex) in vitro. Binding of IL-2 to its receptor leads 
to phosphorylated STAT5 (pSTAT5) [55, 64]. Compared to hIL-2, hIL-2/NARA1 complex 
led, at all concentrations assessed, to very similar pSTAT5 levels in IL-2-responsive CTLL-2 
cells (Fig. 4A) expressing trimeric IL-2Rs. In contrast, mIL-2 complexed to S4B6 at a 2:1 
ratio (mIL-2/S4B6 complex) was about 10-fold less potent than mIL-2 (Fig. 4C, and  [135]), 
consistent with our previous finding that mIL-2/S4B6 complex was discretely less active than 
mIL-2 in mediating proliferation of CD122high CD8+ cells in vitro [134]. These effects might 
result from aforementioned steric clash between S4B6 and CD122 [135]. Conversely, hIL-
2/NARA1 and mIL-2/S4B6 complexes were equipotent to hIL-2 and mIL-2 in driving 
proliferation of CTLL-2 cells (Fig. 4, B and D). Moreover, pSTAT5 induction and 
proliferation of purified human CD8+ T cells (Fig. 4, E and F) was comparable for hIL-2 and 
hIL-2/NARA1 complex. The stimulatory activity of hIL-2/NARA1 complex did not depend 
on cross-linking of two IL-2Rs by the bivalent mAb, as demonstrated by similar pSTAT5 and 
proliferation kinetics of complexes made with either whole mAb versus Fab or F(ab')2 
fragments of NARA1 (Fig. 4, G and H), the latter of which retained efficient hIL-2 binding 
(fig. S7). 
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Figure 4.  Efficient binding and stimulation of T cells by IL-2/NARA1 complex is 
independent of IL-2R crosslinking. (A to D) Phosphorylated STAT5 (pSTAT5) levels (A 
and C) and proliferation (B and D) of CTLL-2 cells in response to titrated hIL-2 versus hIL-
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2/NARA1 complex (A and B) or mIL-2 versus mIL-2/S4B6 complex (C and D). (E and F) 
pSTAT5 levels (E) and proliferation (F) of purified human CD8+ T cells to titrated hIL-2 
versus hIL-2/NARA1 complex. (G and H) pSTAT5 (G) and proliferation (H) of CTLL-2 
cells to hIL-2/NARA1 complex using NARA1 as full antibody, F(ab’)2 fragment, or Fab 
fragment. Shown are mean fluorescence intensity (MFI) of intracellular pSTAT5 levels (A, C, 
E, and G) and proliferation using WST-1 reagent (B, D, F, and H) of two to three 
independent experiments. 
f) hIL-2/NARA1 complex selectively expands anti-tumor effector lymphocytes 
Injection of mice with hIL-2/NARA1 complex for 4 days led to vigorous proliferation and 
expansion of CD122high CD8+ T cells (Fig. 5A) and NK1.1+ DX5+ NK cells in lymph nodes 
and spleen (Fig. 5B-D). Although CD25high CD4+ Treg cells were also stimulated by this 
treatment, expansion of CD8+ T cells was much more prominent (Fig. 5B-D). 
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Figure 5.  Use of IL-2/NARA1 complex mediates efficient expansion of CD122high cells. 
(A to D) Carboxyfluorescein succinimidyl ester (CFSE)-labeled CD8+ T cells from Ly5.1 
(CD45.1)-congenic animals were adoptively transferred to recipient mice, which subsequently 
received 4 daily intraperitoneal injections of PBS, hIL-2, or hIL-2/NARA1 complex. On day 
5, lymph nodes (LNs) were collected and analyzed by flow cytometry for CFSE dilution 
(indicating cell proliferation) in Ly5.1+ CD8+ T cells (A) and for levels of the indicated 
immune subsets (B). Total counts of indicated cell subsets in LNs (C) and spleen (D) of mice 
treated as in A. Data are representative of three independent experiments. 
Treatment of mice harboring a syngeneic intradermal B16-F10 melanoma nodule revealed 
that 1 course of 4 injections of hIL-2/NARA1 complex was sufficient to suppress tumor 
growth by 80%, whereas hIL-2 alone decreased tumor growth only minimally (Fig. 6A). The 
improved anti-tumor response correlated with an increase in CD8+ T cells in tumor-draining 
lymph nodes (TDLNs; Fig. 6B) and tumor-infiltrating lymphocytes (TILs; Fig. 6C). In 
contrast to CD8+ T cells, intratumoral CD25high forkhead box p3 (Foxp3)+ CD4+ Treg cells 
were disfavored by hIL-2/NARA1 complex treatment compared to hIL-2 (Fig. 6C), which 
altogether led to a 5 fold higher ratio of CD8+ to Treg cells (Fig. 6D). A similar paucity was 
observed for CD11b+ Gr-1+ myeloid-derived suppressor cells (Fig. 6C) [112]. Compared to 
their counterparts isolated from mice treated with hIL-2, CD8+ TILs from animals receiving 
hIL-2/NARA1 complex expressed significantly lower programmed death-1 levels (Fig. 6C) 
[146], suggesting the cells were less exhausted. In line with this finding, CD90.1+ gp100-
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specific and CD90.1– polyclonal CD8+ T cells from TDLNs and TILs produced significant 
amounts of interferon-, a crucial cytokine involved in anti-tumor immunity [83], upon ex 
vivo stimulation with gp100 or a polyclonal trigger, respectively (Fig. 6, E and F). Also 
pulmonary nodules of B16-F10 melanoma were reduced by over 77% following 4 injections 
of hIL-2/NARA1 complex, while high-dose hIL-2 treatment achieved only 48% reduction 
(Fig. 6G). However, as expected [60], high-dose hIL-2 treatment caused significant 
pulmonary edema, whereas hIL-2/NARA1 complex was much better tolerated (Fig. 6H). 
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Figure  6.  Use of IL-2/NARA1 complex mediates efficient CD8+ T cell proliferation and 
anti-tumor immune response in the B16-F10 melanoma model. (A to D) Animals were 
injected intradermally with B16-F10 melanoma cells, followed by 4 injections of PBS, hIL-2, 
or hIL-2/NARA1 complex. Shown is tumor volume, with arrow indicating start of treatment 
(A), and indicated immune cell subsets within tumor-draining lymph nodes (TDLNs, B) and 
tumor-infiltrating lymphocytes (TILs, C). Red numbers refer to MFI of programmed death-1 
expression in CD8+ T cells (C). (D) Ratio of CD8+ T cells to CD4+ CD25high FoxP3+ T cells 
in TILs from mice treated as in A. (E and F) Mice were adoptively transferred with CD90.1+ 
gp100-specific T cell receptor-transgenic CD8+ T cells, followed by treatment as in A. Shown 
is IFN-γ production in CD90.1+ gp100-specific and CD90.1– polyclonal CD8+ T cells and 
their quantification from tumor-draining lymph nodes (TDLNs, E) and TILs (F). (G) Animals 
were injected intravenously with B16-F10 melanoma cells, followed by treatment as in A. On 
day 16, lungs were removed and quantification of melanoma nodules was performed, as 
previously described [60]. (H) Mice received PBS, hIL-2 at 1.5 μg (low dose, LD) or 20 μg 
(high dose, HD), NARA1 (15 μg), or hIL-2/NARA1 complex (1.5 μg/15 μg) for 4 days. On 
day 5, lungs were removed in order to determine pulmonary wet weight, as previously 
described [60]. Data are represented as mean ± s.e.m. of three independent experiments, n = 3 
 63 
 
to 4 (A to D), n = 8 (E), n = 3 (F), n = 4 (G), n = 4 (H, PBS, hIL-2 [LD], hIL-2 [HD], 
NARA1), and n = 7 (H, hIL-2/NARA1). For TILs, samples of mice receiving the same 
treatment were pooled prior to analysis. Differences between groups were analyzed using one-
way ANOVA with Bonferroni’s post-test correction. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001. 
g) hIL-2/NARA1 complex immunotherapy is efficacious in a spontaneous melanoma 
model 
Finally, we assessed hIL-2/NARA1 complex treatment in transgenic Tyr::N-RasQ61K Ink4a–/– 
mice, which spontaneously develop metastatic melanoma within 6 months of age [170, 178, 
179]. Using 10 weekly courses of hIL-2/NARA1 complex we were able to prolong tumor-free 
survival in these mice by 2.3–2.7 times (Fig. 7A). Likewise, at time-point of sacrifice, hIL-
2/NARA1 complex-treated mice showed a significant reduction in skin melanoma counts 
(Fig. 7B) and lung metastases (Fig. 7C).These effects correlated with an increase in CD8+ T 
cells, particularly CD44high cells, in lymph nodes and spleen (Fig. 7D). Notably, such 
prolonged treatment did not lead to any overt signs of toxicity or autoimmunity. 
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Figure 7.  Use of IL-2/NARA1 complex mediates efficient tumor and metastasis 
development immune control in a spontaneous melanoma model. (A to D) Skin 
melanoma-free survival (A), skin melanoma counts (B) and lung metastasis counts (C) of 
Tyr::N-RasQ61K Ink4a–/– mice, developing spontaneous melanoma, treated with 10 weekly 
courses of 4 injections of PBS or hIL-2/NARA1 complex. Shown are representative pictures 
of lung metastases. LNs and spleen were collected at the end of the experiment. Shown are 
total counts of indicated cell subsets in LNs (D). Data are represented as mean ± s.e.m. of one 
experiment with n = 7-8. Differences between groups were analyzed using log-rank Mantel-
Cox test (A) and unpaired Student’s t-test (B to C).*P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001. 
h) Conclusion 
Using a rational screening approach we have identified a very rare anti-hIL-2 antibody, which 
based on structural, biophysical and functional data behaves as a high-affinity hCD25-
mimetic. Application of hIL-2/NARA1 complex in established preclinical models of 
metastatic melanoma preferentially stimulates CD8+ T and NK cells and favorably changes 
the intratumoral balance of effector to suppressor-type immune cells. Thus, hIL-2/NARA1 
complex immunotherapy is particularly suitable for achieving strong anti-tumor immune 
responses. Moreover, the properties of hIL-2/NARA1 complex give insight into IL-2 biology 
and IL-2-based selective immunotherapy [55, 56]. 
In conclusion, use of hIL-2/NARA1 complex potentiates IL-2's in vivo bioactivity, while 
reducing its CD25-mediated adverse effects, thus warranting further development of this 
biologic for clinical cancer immunotherapy. 
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i) Supplementary information 
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Fig. S1.  Rational biased screening method for generation of selective anti-human IL-2 
antibodies.  (A and B) Complexes of human (h) IL-2 (1.5 μg) and various anti-hIL-2 
monoclonal antibodies (mAbs; 15μg) were injected daily for 4 consecutive days. On day 5, 
lymph nodes (LNs) and spleen were analyzed for CD122high cells [60, 134], that is CD44high 
CD8+ T cells and CD3– NK1.1+ DX5+ NK cells, versus CD25high CD4+ T cells. The antibodies 
mAbcap and mAbdet were chosen to establish a screening and competition ELISA (A, see 
Methods). Following immunization of mice with hIL-2, serum antibodies and polyclonals 
obtained from hybridomas were screened for hIL-2 binding and for their specificity in the 
competition ELISA. Candidates were diluted in order to obtain monoclonals which were 
further tested for competition and for in vivo expansion of the above-mentioned immune cell 
subsets. This process was repeated until appropriate anti-hIL-2 mAbs were identified (B). 
 
 
Fig. S2.  IL-2 interaction with CD122 and CD25 is different when bound to NARA1 or 
mAbcap.  (A and B) Surface plasmon resonance (SPR) kinetic profiles of hCD122 and hCD25 
interacting with immobilized NARA1 (A) or mAbcap (B) bound to hIL-2 at saturating 
concentration. (C) Equilibrium SPR titration of hCD122 and hCD25 interacting with 
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immobilized mAbcap bound to hIL-2 at saturating concentration. Data are representative of 
three independent experiments. 
 
Fig. S3.  NARA1 binds to IL-2 with high affinity.  SPR kinetic profile of hIL-2 in 3-fold 
dilutions starting at 100 nM interacting with immobilized NARA1. Data are representative of 
three independent experiments. 
 
Fig. S4.  NARA1 does not crossreact with mouse IL-2.  (A and B) SPR kinetic profiles of 
mouse IL-2 (3-fold dilutions starting at 10 nM) with immobilized mAbdet (A) or NARA1 (B). 
Data are representative of two independent experiments. 
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Fig. S5.  NARA1 binding sites differ from S4B6 epitopes on IL-2.  Alignment of human 
and mouse IL-2 sequences with indication of -helices A, B, C, and D, and showing NARA1 
(black boxes) and S4B6 epitopes (pink bands). 
 
Fig. S6.  Binding to NARA1 induces a slight conformational change in hIL-2's helix C.  
Shown are ribbon representations of helix C in unbound hIL-2 (gold; [174]), hIL-2 associated 
with hCD25 (cyan; ref. [174]), D10 hIL-2 mutein ('IL-2 superkine'; purple; [142]), and hIL-2 
bound to NARA1 (turquoise). 
. 
 69 
 
 
Fig. S7.  NARA1 Fab and F(ab')2 fragments retain hIL-2 binding.  Equimolar amounts of 
hIL-2 binding sites of NARA1 full mAb, Fab or (Fab’)2 fragments were added to hIL-2 bound 
to mAbcap. Biotinylated mAbdet was added to check for competition of NARA1 antibody and 
fragments. Data are representative of two independent experiments. 
Antigen Fluorophore Company Serial number 
CD11b BV650 BD Biosciences 563402 
CD122 PE eBioscience 12-1221 
CD25 APC BD Biosciences 557192 
CD3 BV510 BD Biosciences 563024 
CD3 FITC eBioscience 11-0031 
CD4 BV605 BioLegend 100451 
CD44 APC eBioscience 17-0441 
CD45.2 Alexa-700 BioLegend 109822 
CD45.2 BUV395 BD Biosciences 564616 
CD8a Alexa 488 /efluor 450 eBioscience 53-0081/48-0081 
CD8b APC-efluor 780 eBioscience 47-0083 
CD90.1 eFluor 450 eBioscience 48-0900 
FoxP3 PE eBioscience 12-5773 
Gr-1 Alexa 488 eBioscience 53-5931 
IFN-γ PE eBioscience 12-7311 
NK1.1 FITC eBioscience 11-5941 
PD-1 BV605 BioLegend 135219 
STAT5(pY694) Alexa Fluor647 BD Biosciences 562076 
Table S1.  Antibodies used for flow cytometry. 
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2. Epigenetic modulation limits tumor escape during IL-2cx complex immunotherapy 
Adapted from a manuscript submitted to Nature Medicine (Letter format) 
‘The epigenetic repressor Ezh2 controls tumor escape mechanisms during 
immunotherapy’ 
Natalia Arenas-Ramirez1*, Daniel Zingg2*, Rodney A. Rosalia1, Ana T. Antunes2, Jessica 
Haeusel2, Lukas Sommer2† & Onur Boyman1† 
1 Department of Immunology, University Hospital Zurich, University of Zurich, CH-8091 
Zurich, Switzerland 
2 Cell and Developmental Biology, Institute of Anatomy, University of Zurich, 
Winterthurerstrasse 190, CH-8057 Zurich, Switzerland 
* These authors contributed equally to this work. 
† These authors jointly supervised this work. 
 
Correspondence: O.B. (onur.boyman@uzh.ch), L.S. (lukas.sommer@anatom.uzh.ch) 
Keywords: cancer immunoediting, cancer immunosurveillance, immunotherapy, epigenetics, 
Ezh2, melanoma, CTLA-4, IL-2, PD-1, PD-L1 
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 hIL-2/NARA1 antibody complexes (IL-2cx) immunotherapy is followed by selective 
suppression of EZh2 target genes  
Engraftment of murine melanoma cells either of B16-F10 origin or isolated from tumors 
spontaneously developing in Tyr::N-RasQ61K Ink4a–/– mice (termed RIM-3) [170] onto 
syngeneic C57Bl/6 wild-type (Wt) mice (Extended Data Fig. 1) resulted in rapidly-growing 
melanoma nodules. Remarkably, in both B16-F10 and RIM-3 melanomas, interleukin-2 (IL-
2)/NARA1 antibody complex (IL-2cx) [60, 134] immunotherapy caused an increase in Ezh2 
expression (Extended Data Fig. 2). Interestingly, Ezh2high cells were found in tumor areas rich 
in CD45+ leukocytes, whereas tumor sites with little immune cell infiltrates showed lower 
Ezh2 levels (Fig. 1a, b), suggesting that immune cells created a microenvironment promoting 
Ezh2 upregulation. Moreover, gain in Ezh2 was accompanied by a global increase in 
H3K27me3, indicating enhanced Ezh2 activity (Fig. 1c and Extended Data Fig. 2). Indeed, 
IL-2cx treatment of B16-F10-harbouring animals led to an enrichment of Ezh2 and 
H3K27me3 in promoter regions of major histocompatibility complex class I (MHC-I) 
molecules H2-D1 and H2-K1, transporter associated with antigen Tap1 and Tap2, proteasome 
subunits 8 and 9 (Psmb8 and Psmb9), and a set of melanocyte lineage genes, including 
Sox10, Mitf, Dct, Tyr, Tyrp1, Pmel, Mlana and Oca2 (Fig. 1d and Extended Data Fig. 3) [179, 
180]. The products of these targets are involved in antigen processing and presentation and 
constitute known melanoma antigens, such as Trp2 and Pmel (also known as gp100) [181, 
182]. As a result, these Ezh2 target genes (ETGs) became transcriptionally silenced in B16-
F10 and RIM-3 melanomas from IL-2cx-treated mice. In contrast, expression of several genes 
previously connected to melanoma dedifferentiation and metastatic progression, including 
Sox9, Snai1, Zeb1 and CD271, substantially increased (Fig. 1e and Extended Data Fig. 4) 
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[144, 183-185]. Notably, these changes were again most apparent in tumor areas with high 
immune cell infiltration (Fig. 1f, g). To demonstrate that IL-2cx-induced changes in gene 
expression were dependent on Ezh2, we blocked Ezh2 function using either a short hairpin 
RNA against Ezh2 transcript (shEzh2) or GSK503, an EZH2-specific chemical inhibitor 
[173]. RNA interference (RNAi) effectively reduced Ezh2 levels in vitro and in vivo, while 
both approaches led to a considerable loss of H3K27me3 in melanoma samples, even in 
animals receiving IL-2cx (Fig. 1c and Extended Data Fig. 2). Importantly, upon Ezh2 
silencing, loss of Ezh2 and H3K27me3 was observed specifically in promoter regions of the 
aforementioned ETGs shown to be downregulated upon IL-2cx immunotherapy (Fig. 1d and 
Extended Data Fig. 3). Accordingly, Ezh2 inactivation resulted in upregulation of these ETGs 
and reduced expression of dedifferentiation genes, despite concomitant IL-2cx 
immunotherapy (Fig. 1e and Extended Data Figs. 4 and 5). This was most conspicuous for 
areas rich in CD45+ immune cell infiltrates (Fig. 1f, g).  
 73 
 
 
Figure 1.  Immunotherapy-induced Ezh2 promotes melanoma dedifferentiation and loss 
of immunogenicity. a, b, Immunofluorescence staining for Ezh2 and CD45 and 
quantification of Ezh2high CD45– cells in areas poor or rich in CD45+ cells (CD45+ n < 5 
versus n > 25 / field) in B16-F10 and RIM-3 from PBS or IL-2cx-treated mice. Scale bars, 50 
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m. c, Quantification of Western blots for H3K27me3 (Extended Data Fig. 2c, d) on B16-F10 
and RIM-3 following IL-2cx and/or Ezh2 inactivation with shEzh2 or GSK503. d, ChIP for 
Ezh2 and H3K27me3 and subsequent qPCR in promoter regions of selected loci on B16-F10 
after IL-2cx and/or Ezh2 silencing with shEzh2. Heat maps show values relative to intergenic 
region 1 (Interg1) and control (shCo) and summarise data from Extended Data Fig. 3. e, RT-
qPCR for selected genes on B16-F10 and RIM-3 after IL-2cx and/or Ezh2 inactivation with 
shEzh2 or GSK503. Heat maps show values relative to control (shCo or PBS) and summarise 
data from Extended Data Fig. 4. f, g, Immunofluorescence stainings for Mitf, Pmel, Zeb1 and 
CD45 on RIM-3 following PBS, IL-2cx, GSK503, or GSK503 + IL-2cx to quantify mean 
fluorescence intensities (MFI) of Mitf, Pmel and Zeb1 in areas poor or rich in CD45+ cells 
(CD45+ n < 5 versus n > 25 / field). Scale bars, 50 m. Data are represented as mean ± 
standard error of the mean (s.e.m.) of n = 6 (b), n = 5 (g), median ± 100% range of n = 7 (c) 
of two independent experiments. P-values calculated with analysis of variance (ANOVA) and 
Fisher’s least significant difference (LSD) test. NS, not significant, *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001. 
 Ezh2 blockade synergizes with IL-2cx immunotherapy favoring the intratumoral 
accumulation of cytotoxic T cells 
Our data suggested that Ezh2 inactivation was sufficient to reverse immunotherapy-induced 
immune escape in melanoma cells. Indeed, Ezh2 RNAi or IL-2cx as individual approaches 
were able to slow down B16-F10 growth in vivo, although tumors ultimately progressed. 
Significantly, a combination of both IL-2cx and Ezh2 RNAi was most potent, reducing tumor 
volume by more than 80% (Fig. 2a and Extended Data Fig. 1). Similar effects were observed 
in mice harboring B16-F10 following injection of GSK503 + IL-2cx or GSK503 plus a 
blocking monoclonal antibody (mAb) against CTLA-4 (Fig. 2b, c and Extended Data Fig. 1). 
To uncover the mechanism of these anti-tumor effects, we dissected the cellular immune 
composition within tumors, analysing tumor-infiltrating lymphocytes (TILs), in comparison 
to tumor-draining lymph nodes (TDLNs) and spleen. Compared to control, IL-2cx 
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immunotherapy led to increased CD8+ T cell counts in TILs, TDLNs and spleen, unlike 
GSK503, which affected neither proliferation nor expansion of these cells (Fig. 2d, e and 
Extended Data Fig. 6). Strikingly, accumulation of CD8+ T cells was more prominent upon 
GSK503 + IL-2cx than in IL-2cx monotherapy, while CD8+ T cell levels were comparable for 
both treatments in TDLNs and spleen (Fig. 2d, e and Extended Data Fig. 7). Contrarily, 
percentages and counts of other T cell subsets, including total CD4+ T cells, CD4+ CD25+ 
FoxP3+ Treg cells, natural killer (NK) cells, MHC-II+ B and antigen-presenting cells, and 
CD11b+ Gr-1+ MDSCs were not significantly changed in TILs upon treatment, although some 
differences were noted in TDLNs and spleen (Fig. 2d, e and Extended Data Fig. 8). These 
effects resulted, upon GSK503 + IL-2cx combination therapy, in favorable ratios of CD8+ T 
cells over Treg cells (15:1) and over MDSCs (45:1), respectively (Fig. 2f, g). These ratios 
were lower upon IL-2cx monotherapy and barely changed during GSK503 treatment in 
comparison to control animals. Thus, the anti-tumor effects of IL-2cx combined with Ezh2 
blockade correlated with accumulation of effector CD8+ T cells selectively within the tumor 
in disfavor of suppressor-type immune cells. 
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Figure 2.  Ezh2 inactivation enhances anti-melanoma immunotherapy by facilitating 
intratumoral CD8+ T cell accumulation. a–c, Tumor growth kinetics in mice engrafted 
with shCo or shEzh2-transfected B16-F10 melanoma cells and receiving PBS or IL-2cx 
(a), engrafted with B16-F10 cells and receiving PBS, IL-2cx, GSK503, or GSK503 + IL-
2cx (b), or PBS, anti-CTLA-4 mAb, GSK503, or GSK503 + anti-CTLA-4 mAb (c). Black 
arrows indicate time-point of treatment start. d, e, Flow cytometry analyses of tumor-
infiltrating lymphocytes (TILs) and tumor-draining lymph nodes (TDLNs) from mice 
harbouring B16-F10 and treated as in (b), with quantifications of total cell counts (e, left 
axes, coloured bars) and percentages (e, right axes, square points) of indicated immune 
cell subsets. f, g, Ratios of CD8+ T cells versus CD4+ CD25+ FoxP3+ regulatory T cells (f) 
 77 
 
and CD3– CD11b+ Gr-1+ myeloid-derived suppressor cells (g). Data are represented as 
mean ± s.e.m. of n = 15 (a), n = 25 (b), n = 4 (c, PBS), n = 6 (c, GSK503), n = 5 (c, anti-
CTLA-4 +/- GSK503), n = 6 (e, CD8+ and CD4+ TILs), n = 4 (e, CD4+ CD25+ FoxP3+ 
and CD3– CD11b+ Gr-1+ TILs), n = 17 (e, CD8+, CD4+ and CD4+ CD25+ FoxP3+ 
TDLNs), n = 9 (e, CD3– CD11b+ Gr-1+ TDLNs), n = 4 (f) and n = 3 (g) of three (a), six 
(b, d–g), and two independent experiments (c). For TILs, samples of mice receiving the 
same treatment were pooled prior to analysis. P-values calculated with ANOVA and 
Fisher’s LSD test (a–c), unpaired Student’s t-test (e, total cell counts). *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001. 
 Ezh2 blockade and IL-2cx immunotherapy combination suppress the PD-1/PDL-1 
pathway in the tumor site 
Negative costimulatory molecules, including PD-1 and its ligand PD-L1, contribute to an 
immunosuppressive tumor microenvironment [83, 105, 108]. High PD-1 expression marks 
effector T cells that become exhausted when faced with antigen persistance and progressively 
lose effector functions, including IFN- production [145]. In contrast to TDLNs where PD-1 
levels on CD8+ T cells were low in all groups, CD8+ T cells from TILs of control mice 
expressed very high levels of PD-1, both in percentages and mean fluorescence intensity 
(MFI) (Fig. 3a). Conversely, percentages of PD-1+ CD8+ T cells were roughly halved in TILs 
of animals receiving either IL-2cx or GSK503, and even further decreased with combination 
therapy (Fig. 3a, b), indicating that GSK503 + IL-2cx prevented tumor-infiltrating CD8+ T 
cells from rapid exhaustion.PD-L1 is frequently elevated on tumor cells [105, 108]. 
Interestingly, IL-2cx immunotherapy promoted PD-L1 upregulation in Pax3+ melanoma cells, 
particularly in areas rich in CD3+ TILs (Fig. 3c, d). This was in line with the observed 
increase of Zeb1 upon IL-2cx (Fig. 1 and Extended Data Fig. 4), which has been shown to 
transcriptionally enhance PD-L1 expression [186]. However, Ezh2 inactivation led to reduced 
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PD-L1 mRNA levels and a decrease in PD-L1+ Pax3+ melanoma cells, which was maintained 
during concomitant IL-2cx treatment (Fig. 3c, d and Extended Data Fig. 9). The 
downregulation of the immunosuppressive PD-1PD-L1 axis by Ezh2 blockade plus IL-2cx 
combination therapy was remarkably efficient, even when treatment was initiated only after 
the formation of visible tumor nodules. Consequently, addition of a blocking anti-PD-1 mAb 
did not further improve the anti-tumor effects of GSK503 or IL-2cx (Fig. 3e). 
 
Figure 3.  Immunotherapy and Ezh2 blockade synergistically suppress PD-1PD-L1 
axis. a, b, PD-1 expression on CD8+ T cells by percentages (a, b) and MFI (a) in TDLNs (a, 
upper panels) and TILs (a, lower panels, and b). c, d, Immunofluorescence staining for Pax3, 
PD-L1 and CD3 on RIM-3 following PBS, IL-2cx, GSK503, or GSK503 + IL-2cx, and 
 79 
 
quantification of Pax3+ PD-L1+ cells in areas poor or rich in CD3+ cells (CD3+ n < 5 versus n 
> 25 / field). Scale bars, 50 m. e, Growth of RIM-3 tumors during IL-2cx, anti-PD-1 mAb, 
GSK503, or indicated combinations thereof. Black arrows indicate time-point of treatment 
start. Data are represented as mean ± s.e.m. of n = 5 (b, d, e) of six (b) and two independent 
experiments (e). For TILs, samples of mice receiving the same treatment were pooled prior to 
analysis. P-values calculated using ANOVA and Fisher’s LSD test. *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001. 
 IFN-γ producing CD8+ T cells mediate the anti-tumor effects observed upon IL-2cx 
immunotherapy and Ezh2 blocked 
The demonstration in animals receiving Ezh2 inhibitor plus IL-2cx that CD8+ T cells 
predominated TILs and expressed very low PD-1 levels suggested that tumor control 
depended on these effector cells. We thus compared combination therapy using GSK503 + 
IL-2cx in Wt mice versus animals lacking both T cell receptor (TCR)+ and TCR+ T cells 
(Tcrbd–/– mice). Moreover, we used mice deficient in the recombinase-activating gene 1 
(Rag1–/–), as they lack T and B cells, but harbor functional NK cells. The anti-melanoma 
effect of combination therapy was lost in both Tcrbd–/– and Rag1–/– mice (Fig. 4a), thus 
demonstrating that T cells, but neither B nor NK cells, exerted the tumoricidal effects. Further 
experiments using specific depleting mAbs showed that CD8+, but not CD4+ T cells, played a 
crucial role in the anti-tumor response. Thus, during GSK503 + IL-2cx treatment, tumor 
control was lost in animals injected with anti-CD8 depleting mAb, while mice receiving anti-
CD4 depleting mAb were able to fully suppress tumor growth (Fig. 4b). Previously, CD8+ T 
cell anti-tumor function has been linked to IFN- and TNF- production [83, 115, 144]. 
Notably, the anti-tumor effect of IL-2cx plus Ezh2 blockade depended on IFN- production, 
whereas TNF- was dispensable or even pro-tumorigenic, as demonstrated using Ifng–/– and 
Tnfa–/– mice (Fig. 4c). In line with these data, TNF- production by CD4+ and CD8+ T cells 
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was not significantly altered in GSK503 + IL-2cx-treated animals (Extended Data Fig. 10). 
However, both CD90.1– polyclonal CD8+ and, upon adoptive transfer, also CD90.1+ Pmel-
specific TCR-transgenic CD8+ T cells produced high IFN- levels when isolated from mice 
receiving GSK503 + IL-2cx combination therapy, whereas IFN- production was lower in 
cells originating from the other groups as well as in CD4+ T cells (Fig. 4d and Extended Data 
Fig. 10). This correlated with the strong intratumoral Pmel upregulation upon Ezh2 
inactivation (Fig. 1d-g and Extended Data Figs. 3 and 4) and suggested that intratumoral IFN-
 production facilitated killing of tumor cells. Accordingly, ex vivo cytotoxic activity of CD8+ 
T cells, as assessed using the degranulation marker CD107a, was highest following 
combination immunotherapy, as shown by higher numbers of CD107a+ CD8+ T cells within 
TILs from animals treated with IL-2cx plus Ezh2 blockade (Fig. 4e). 
Figure 4.  Ezh2 inhibition plus IL-2 immunotherapy depends on IFN--producing 
cytotoxic CD8+ T cells. a–c, Growth of B16-F10 tumors during PBS versus GSK503 + IL-
2cx combination therapy in Wt, Tcrbd–/–, and Rag1–/– (a), Wt depleted of CD4+ or CD8+ T 
cells using mAbs (b), or Ifng–/– and Tnfa–/– mice (c). Black arrows indicate time-point of 
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treatment start, red arrow start of mAb injection. d, IFN- production by CD90.1– endogenous 
(upper) and CD90.1+ Pmel-specific CD8+ T cells (lower panels) from TDLNs of B16-F10-
grafted mice receiving PBS, IL-2cx, GSK503, or GSK503 + IL-2cx. e, Degranulating 
CD107a+ CD8+ T cells per mm3 tumor from mice treated as in (d). Data are represented as 
mean ± s.e.m. of n = 8 (a), n = 6 (b), n = 9 (c), n = 2 (e) of two (a–c, e) and three independent 
experiments (d). For TILs, samples of mice receiving the same treatment were pooled prior to 
analysis. P-values calculated with ANOVA and Bonferroni correction (a–c), unpaired 
Student’s t-test (e). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
 Conclusion 
Collectively, we show that, during immunotherapy, increased Ezh2 activity reshapes the 
epigenomic landscape resulting in melanoma dedifferentiation, loss of immunogenicity and 
upregulation of the PD-1PD-L1 axis. These mechanisms favour tumor cell-intrinsic and 
extrinsic immune escape through exhaustion of IFN--producing cytotoxic CD8+ T cells and 
likely complement the recently demonstrated epigenetic repression of CD8+ T cell-trafficking 
to the tumor site [187]. Therefore, Ezh2 inactivation locks melanoma in an immunogenic state 
and facilitates efficient CD8+ T cell-mediated anti-tumor responses during immunotherapy. 
Thus, targeting of EZH2 is an attractive strategy to combine with cancer immunotherapy. 
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 Supplementary information 
 
Extended Data Figure 1.  Experimental setups used. a, Strategy used to administer IL-
2/anti-IL-2 antibody complexes (IL-2cx) to mice harbouring shCo or shEzh2-transfected B16-
F10 melanoma. b–e, Strategies used to administer IL-2cx, anti-CTLA-4 monoclonal antibody 
(mAb), anti-PD-1 mAb immunotherapy and GSK503 Ezh2 inhibitor to mice harbouring B16-
F10 or RIM-3 (Tyr::N-RasQ61K Ink4a–/– melanoma 3). f, g, Strategies used to deplete CD4+ 
and CD8+ cells (f) or to adoptively transfer CD90.1+ CD8+ Pmel T cells (g) in mice 
harbouring B16-F10 and treated as in c. 
i.d., intradermal; s.c., subcutaneous. 
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Extended Data Figure 2.  Ezh2 inactivation reverses IL-2cx-promoted Ezh2 activity.a, 
RT-qPCR for Ezh2 on B16-F10 and RIM-3 melanoma biopsies after IL-2cx application as in 
Extended Data Fig. 1.b, RT-qPCR for Ezh2 on in vitro-cultured B16-F10 cells after 
transfection with a scrambled shRNA (shCo)-expressing or a shEzh2-expressing plasmid. c–e, 
Western blots for Ezh2 and H3K27me3 on B16-F10 (c) and RIM-3 (d) after IL-2cx 
application and/or Ezh2 inactivation using shEzh2 or GSK503 and quantifications of Ezh2 
protein levels (e). H3K27me3 level quantifications are shown in Fig. 1c. Data are represented 
as median ± 100% range of n = 6 (a), mean ± s.e.m. of n = 3 (b) of two independent (a, e) and 
one experiment (b). P values calculated with Student’s t-test. NS, not significant, *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001. 
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Extended Data Figure 3.  Ezh2 silencing reverses IL-2cx-promoted Ezh2 and H3K27me3 
enrichment at promoters of selected loci. a, Graphical representation of model system and 
colour coding for experimental groups. b, ChIP using IgG control antibody (IgG-Co) and 
antibodies against Ezh2 and H3K27me3 and subsequent qPCR for promoters of selected loci 
and intergenic region 1 (Interg1) on B16-F10 melanomas after IL-2cx administration and/or 
Ezh2 depletion using shEzh2. c, d, Ezh2 and H3K27me3 specific ChIP and subsequent qPCR 
for promoters of selected loci and Interg1 on B16-F10 melanomas after IL-2cx administration 
and/or Ezh2 depletion using shEzh2. Data summarized in heat maps of Fig. 1d. Data are 
represented as mean of n = 2 (b), median ± 100% range of n = 5 (c, d) of one experiment (a) 
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and two independent experiments (c, d). P-values calculated using ANOVA and Fisher’s LSD 
test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
 
Extended Data Figure 4.  Ezh2 silencing reverses IL-2cx-promoted changes in gene 
expression. a, e, i, Graphical representations of model systems and colour coding for 
experimental groups. b–d, f–h, RT-qPCR for selected genes on B16-F10 or RIM-3 
melanomas after IL-2cx administration and/or Ezh2 inactivation using shEzh2 or GSK503. 
Data summarized in heat maps of Fig. 1e. j–l, RT-qPCR for selected genes on B16-F10 
melanomas after Ezh2 inactivation using either shEzh2 or GSK503. Data are represented as 
median ± 100% range of n = 6 (b–d), n = 4 (f–h), mean ± s.e.m. of n = 3 (j–l, shCo), n = 4 (j–
l, shEzh2, shCo + GSK503) of two independent experiments (a–h) and one experiment (i–l). 
P values calculated with ANOVA and Fisher’s LSD test. *P < 0.05, **P < 0.01, ***P < 
0.001, ****P < 0.0001. 
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Extended Data Figure 5.  Ezh2 silencing induces in vitro B16-F10 differentiation. a, 
Graphical representations of model system and colour coding for experimental groups. b–d, 
RT-qPCR for selected genes on B16-F10 cultures after Ezh2 silencing using shEzh2. e, 
Immunofluorescent staining for Dct and Tyrp1 on B16-F10 cells after Ezh2 inactivation using 
either shEzh2 or GSK503. Scale bars, 50 m. f, Macroscopic picture of B16-F10 cell pellets 
after Ezh2 silencing using shEzh2. Data are represented as mean ± s.e.m. of n = 3 of two 
independent experiments. P-values calculated with ANOVA and Fisher’s LSD test. *P < 
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.  
 
Extended Data Figure 6.  Ezh2 inhibition does not affect cell proliferation or expansion 
of T cells and NK cells. a, b, Mice received PBS, IL-2cx, GSK503, or GSK503 + IL-2cx for 
four days. On the last 3 days animals also received bromodeoxyuridine (BrdU; 0.8 mg/ml) in 
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their drinking water. On day 5, mice were euthanized and analysed for proliferating BrdU+ 
CD4+ and CD8+ T cells (a) and total cell counts of CD8+ T cells, memory-phenotype 
CD44high CD8+ T cells, CD4+ T cells, CD4+ CD25+ forkhead box P3 (FoxP3)+ regulatory T 
cells, and CD3– NK1.1+ DX5+ natural killer (NK) cells in spleen (b).  Data are represented as 
mean ± s.e.m. of n = 2 (PBS), n = 3 (GSK503 and IL-2cx), n = 4 (GSK503 + IL-2cx) of two 
independent experiments.  
 
Extended Data Figure 7.  Effects on T cell subsets and suppressor-type immune cells 
upon combination of Ezh2 inhibition and IL-2cx immunotherapy. a-d, Flow cytometry 
analyses of indicated markers in spleen (a and c) and tumor-draining lymph nodes (TDLNs; 
c) from mice harbouring B16-F10 and treated as in Fig. 2b, and quantification of total cell 
counts and percentages of CD3+ CD8+ T cells, CD3+ CD4+ T cells, CD4+ CD25+ FoxP3+ 
 88 
 
regulatory T cells, and CD3– CD11b+ Gr-1+ myeloid-derived suppressor cells (MDSCs) in 
spleen (b) and CD44high CD8+ T cells in spleen and TDLNs (d). Data are represented as mean 
± s.e.m. of n = 17 (b, CD8+, CD4+ and CD4+ CD25+ FoxP3+), n = 9 (b, CD3– CD11b+ Gr-1+), 
and n = 14 (d, CD44high CD8+ T cells) of six independent experiments. P-values calculated 
with unpaired Student’s t-test (b, d). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
 
Extended Data Figure 8.  Effects of combination of Ezh2 inhibition and IL-2cx 
immunotherapy on NK cells, B cells, and antigen-presenting cells. a,b, Flow cytometry 
analyses of indicated markers in tumor-infiltrating lymphocytes (TILs), TDLNs and spleen 
from mice harbouring B16-F10 and treated as in Fig. 2b, and quantification of total cell 
counts and percentages of CD3– NK1.1+ NK cells (top three panels) and CD3– MHC-II+ B 
and antigen-presenting cells (lower three panels). Data are represented as mean ± s.e.m. of n = 
3 (b, CD3– NK1.1+ TILs), n = 6 (b, CD3– NK1.1+ TDLNs and spleen), n = 3 (b, CD3– 
MHCII+ TILs), n = 10 (b, CD3– MHCII+ TDLNs), and n = 9 (b, CD3– MHCII+ spleen) of six 
independent experiments. For TILs, samples of mice receiving the same treatment were 
pooled prior to analysis. P-values calculated using unpaired Student’s t-test (b). *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001. 
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Extended Data Figure 9.  Ezh2 inactivation promotes PD-L1 downregulation. a, RT-
qPCR for PD-L1 on B16-F10 and RIM-3 melanomas after IL-2cx administration and/or Ezh2 
inhibition using GSK503. b, RT-qPCR for PD-L1 on B16-F10 melanomas after Ezh2 
inactivation using either shEzh2 or GSK503. c, RT-qPCR for PD-L1 on B16-F10 cultures 
after Ezh2 silencing using shEzh2. Data are represented as median ± 100% range of n = 6 (a), 
mean ± s.e.m. of n = 3 (b, shCo), n = 4 (b, shEzh2, shCo + GSK503), n = 3 (c) of two 
independent experiments (a, c) and one experiment (b). P-values calculated with ANOVA 
and Fisher’s LSD test (a, b), or Student’s t-test (c). *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001. 
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Extended Data Figure 10.  TNF- and IFN- production in T cell subsets upon Ezh2 
inhibition plus IL-2cx therapy. a–c, TNF- production by CD90.1– endogenous (upper) and 
CD90.1+ Pmel-specific CD8+ T cells (lower panels) (a), TNF- production by endogenous 
CD4+ T cells (b), and IFN- production by endogenous CD4+ T cells (c) from TDLNs of B16-
F10-grafted mice receiving PBS, IL-2cx, GSK503, or GSK503 + IL-2cx as in Fig. 2b. Data 
are representative of two independent experiments. 
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Antigen Fluorophore Company Serial number 
CD107a PE eBioscience 12-1071 
CD11b BV650 BD Biosciences 563402 
CD122 PE eBioscience 12-1221 
CD25 APC BD Biosciences 557192 
CD3 BV510 BD Biosciences 563024 
CD3 FITC eBioscience 11-0031 
CD4 BV605 BioLegend 100451 
CD44 APC eBioscience 17-0441 
CD45.2 Alexa-700 BioLegend 109822 
CD45.2 BUV395 BD Biosciences 564616 
CD8a Alexa 488 /efluor 450 eBioscience 53-0081/48-0081 
CD8b APC-efluor 780 eBioscience 47-0083 
CD90.1 eFluor 450 eBioscience 48-0900 
FoxP3 PE eBioscience 12-5773 
Gr-1 Alexa 488 eBioscience 53-5931 
I-A/E-A BV711 BD Biosciences 563414 
IFN- PE eBioscience 12-7311 
NK1.1 FITC eBioscience 11-5941 
PD-1 BV605 BioLegend 135219 
TNF- APC eBiosciences 17-7321 
Supplementary Table 1.  FACS antibodies. 
 
Antigen Company Serial number Applications / Dilutions 
-Actin Sigma-Aldrich A5316 WB, 1:10’000 
CD3 Cell Signaling Technology 4443 IF, 1:100 
CD45 BD Biosciences 550539 IF, 1:100 
Dct Santa Cruz Biotechnology sc-10451 IF, 1:500 
Ezh2 Cell Signaling Technology 3147 ChIP, 1:100; IF, 1:200; WB, 1:1’000 
H3K27me3 Cell Signaling Technology 9733 ChIP, 1:100; WB, 1:1’000 
Histone 3 Cell Signaling Technology 3638 WB, 1’000 
Mitf H. Arnheiter Lab, NIH (ref. S1)  LH7 IF, 1:100 
Pax3 Life Technologies 38-1801 IF, 1:200 
PD-L1 R&D Systems AF1019 IF, 1:100 
Pmel Novus Biologicals NBP1-69571 IF, 1:100 
Tyrp1 V. Hearing Lab, NIH (ref. S2) PEP1 IF, 1:500 
Zeb1 Bethyl Laboratories IHC-00419 IF, 1:100 
Supplementary Table 2.  Primary antibodies. 
S1. Debbache, J. et al. In vivo role of alternative splicing and serine phosphorylation of the microphthalmia-associated 
transcription factor. Genetics 191, 133–144 (2012). 
S2. Kobayashi, T. & Hearing, V. J. Direct interaction of tyrosinase with Tyrp1 to form heterodimeric complexes in vivo. J 
Cell Sci 120, 4261–4268 (2007). 
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Fluorophore Specificity Company Serial number Applications / Dilutions 
Alexa488 goat Jackson ImmunoResearch 705-545-147 IF, 1:500 
Alexa488 rabbit Jackson ImmunoResearch 711-545-152 IF, 1:500 
Alexa647 rabbit Jackson ImmunoResearch 111-605-003 IF, 1:500 
Cy3 rat Jackson ImmunoResearch 712-165-153 IF, 1:500 
IRDye-800CW mouse LI-COR Biosciences 926-32212 WB, 1:10’000 
IRDye-680LT rabbit LI-COR Biosciences 926-68023 WB, 1:10’000 
Supplementary Table 3.  Secondary antibodies. 
 
Gene Forward sequence Reverse sequence 
CD271 ATGGATCACAAGGTCTACCCC GGAGCAATAGACAGGAATGAGG 
Dct CCTGAATGGGACCAATGCCT AGGCATCTGTGGAAGGGTTG 
Ezh2 GTGACCACAGGATAGGCATCT CAAGGGATTTCCATTTCTCG 
H2-D1 GGAGCTATGGCCATCATTGGA TCTCGGAGAGACATTTCAGAGC 
H2-K1 CTGGAGCTGTGGTGGCTTT GACAGATCAGAGGTCTGGGAG 
Mitf CCCCAAGTCAAATGATCCAG GCAACTTCCGGATGTAGTCC 
Mlana CTTATCGGCTGCTGGTACTG CTCTTGAGAAGACAGTCGGC 
Oca2 TGTTGGAGAACAGACTGCCC ATGATGCCAAGGCTGAGACC 
PD-L1 GGACTACAAGCGAATCACGC TTCTGGATAACCCTCGGCCT 
Pmel GGGGATGCATTTGAGCTGAC CTGGCACCCTGGTGATGAAA 
Psmb8 AGCATCCAAGCTGCTTTCCAA CCGAGTCCCATTGTCATCTACG 
Psmb9 GGTTCCGGAAGCTCCTACAT AGAGCCATCTCGGTTCATGG 
Snai1 GTGGAAAGGCCTTCTCTAGGC GGTTGGAGCGGTCAGCAAAA 
Sox9 ATGCTATCTTCAAGGCGCTG TTGCACGTCGGTTTTGGGA 
Sox10 GAAGAAGGCTCCCCCATGTC GCTCTGTCTTTGGGGTGGTT 
Tap1 TCCCTCAGGGCTATGACACA ATAAGCAGGAGTGGCTTCCG 
Tap2 ACTGTGAGGACGCTCAAGTG TAACTGGCCCCCTTTTTCCC 
Tyr GTACTTGGGAGGTCGTCACC GTCCCTCAGGTGTTCCATCG 
Tyrp1 GCACACTTTCACTGATGCGG TAGGTGCGTTTTCCAACGGG 
Usf1 CAGGGCTCAGAGGCACTACT GCTCCCTCCCTGCAATACTT 
Zeb1 GATCCAGCCAAACGGAAACC TGGCGTGGAGTCAGAGTCAT 
Supplementary Table 4.  Mouse RT-qPCR primers. 
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Promoter Forward sequence Reverse sequence 
Dct CTGGGACACATGAGCCCAATA GACCCTAAGTGCACAATGAAGC 
H2-D1 TTGTATTCCCGGAAGTGACCTT TCACTGTTTCCTAACCTCCACC 
H2-K1 ACTTTAAGGAAAAGCCTCTCTCTCC AAAGCCTCTTCCGGGAATACAA 
Interg1 GCTCCGGGTCCTATTCTTGT TCTTGGTTTCCAGGAGATGC 
Mitf CGTGTCCTCGCAGATGTCTAAA CGGTTTGCTTCAAGGATACAGAC 
Mlana CAGACACCCATTAGGAATCCAAAAC ATGTGAAGACGGCTTCTCTGG 
Oca2 CTGGCTTCTACAGCAAGGCT CCAGCCCCCTCTTGAGAATG 
Pmel GCTGCCCATCAGTGAACTCT GGGAAGAAGGAAAGGGCCAG 
Psmb8 ACACATGAAAAGGCCCGACT GCACAGGGGTCTTTAGGTCC 
Psmb9 CCCCTTAACTTGCTTGCGTG CCAGAGACAGGTGACGACAG 
Sox10 AAACCCAAGCTGAGTCCAGG CTTCATCCCCAACACCCAGG 
Tap1 GAGAAGAACACGACAGGCCA TCAGGCTGTTCTGGAAGCTG 
Tap2 GGCTCAGGCAAGTTTTCTCAAC GACCTCCGAGCATGTTTTAAGAAG 
Tyr CATGTGCTTTGCAGAAGATAAAAGC GGAGTGACTATCACATGTTTTGGC 
Tyrp1 GTGTGACATTGGCCTTAGTTCG ACGCTGAAGAGATTTTGCTTTCG 
Supplementary Table 5.  Mouse ChIP primers. 
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VI. Conclusion and discussion 
The concept of cancer immunotherapy has now opened the way for the development of 
therapeutics, which stimulate and potentiate the host's immune response against tumor cells. 
Different pharmaceuticals have been developed and approved for the treatment of metastatic 
melanoma such as recombinant IL-2 [188] and/or immuno-modulatory antibodies [189]. 
Although therapeutic benefits can be durable, only a subset of patients responds to current 
immunotherapies. Moreover, the use of most if not all immunotherapies is accompanied with 
severe side effects, many of which relate to the induction of autoimmunity and pro-
inflammatory conditions [190]. Taken together, the low efficacy and the high incidence of 
therapy-related adverse effects represent a considerable clinical challenge that needs to be 
overcome by further pre-clinical research.  
Taking these points into consideration, the first aim of the thesis was to develop a unique 
mAb to hIL-2, which could be further developed as high efficacy and low toxicity cancer 
immunotherapy for clinical use. We devised a rational approach for the generation of an anti-
hIL-2 antibody to overcome the limitations of high-dose recombinant IL-2 currently used in 
the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma 
patients. Following this approach we obtained an anti-hIL-2 mAb, named NARA1, which we 
could characterize in great detail combing structural, biophysical, and in vitro and in vivo 
functional analyses. Based on these results, we concluded that NARA1 binds with high 
affinity to the CD25 binding site of IL-2 acting as a high-affinity mimic of this IL-2-receptor 
subunit, allowing preferential stimulation of CD122high cells (CD8+ T cells and NK cells) but 
disfavoring CD25+ Treg cell proliferation and CD25+ endothelial cell damage in vivo. The use 
of such antibody does not only preferentially direct IL-2 to the dimeric IL-2R but also allows 
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lowering the dose of IL-2 required for optimal in vivo bioactivity by increasing the half-life of 
IL-2. In line with these effects, using hIL-2/NARA1 complexes we were able to significantly 
better control tumor growth in murine models of melanoma which led to improved survival of 
mice engrafted with melanoma cells or in animals spontaneously developing metastatic 
melanoma. 
For the clinical development of NARA1 and hIL-2/NARA1 complexes, some properties of 
hIL-2 and the interaction of hIL-2 with NARA1 merit consideration. Although hIL-2 and 
NARA1 are premixed prior to injection and associate with each other with high affinity, the 
two components could potentially detach in vivo, leading to unbound hIL-2 and NARA1. 
However, even if the hIL-2/NARA1 complex were to dissociate fully, the systemic levels of 
hIL-2 would be 20-fold lower compared to the high-dose IL-2 doses administered currently to 
cancer patients. At such low concentrations, IL-2-related side effects will be either absent or 
much milder. The free NARA1 antibody could in turn bind endogenous hIL-2 and thus 
generate hIL-2/NARA1 complexes favoring the stimulation of CD122high cells, similar to 
what has been observed with the anti-mIL-2 antibody S4B6 [134]. An additional therapeutic 
application of NARA1 could be the direct administration of the antibody to complex 
endogenous IL-2. However, for this approach to be successful systemic IL-2 levels need to be 
sufficiently high. In a clinical setting, the administration of NARA1 as a single agent could 
boost the efficacy of immune checkpoint blockade inhibitors in patients, especially when one 
considers recent data showing that CTLA-4 blockade increases IL-2-producing effector cells 
and reduces tumor growth [191].  
Alternatively, the dissociation of NARA1 from IL-2 could also be overcome with the 
development of a fusion protein where the antibody and the cytokine will be linked with a 
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flexible linker as previously described for the anti-mIL-2 mAb S4B6 [192]. Nevertheless, to 
date, we cannot be sure that the in vivo effects observed using hIL-2/NARA1 complex would 
be reflected in the fusion protein. It is not known if the cytokine needs to dissociate from the 
antibody in order to get optimal in vivo selectivity for the dimeric receptor. To answer this 
question one would need to investigate IL-2 binding and signaling properties as well as 
internalization and recycling of hIL-2/NARA1 complexes and corresponding fusion proteins 
side by side with free recombinant IL-2. 
Given the complexity of the immune system, combination of hIL-2/NARA1 complex with 
other immunotherapies, such as ACT, tumor peptide-specific vaccination, and immune 
checkpoint inhibitors, could induce stronger anti-tumor responses and lead to protective 
immunity in patients. We have indeed observed synergistic effects when combining hIL-
2/NARA1 complex with particular checkpoint inhibitors or peptide-specific approaches 
(unpublished data). 
The disadvantages of IL-2 can potentially also be circumvented with the development of IL-2 
mutants (IL-2 muteins) [55, 142, 143], but further engineering may be needed in order to use 
them in a clinical setup. Recombinant human protein drugs are mostly recognized by the body 
as ‘self’ as shown by the administration of recombinant G-CSF (Neupogen) or hIL-2  
(Proleukin) with less than 3% and 1% reported immunogenicity, respectively [193]. 
Moreover, the efforts done in predicting T cell epitopes and depleting them from the proteins 
therapeutics have been successful for humanized or human antibodies showing only low 
levels of anti-drug antibodies (ADAs) in patients to date [193]. However, immune tolerance 
of recombinant proteins can be lost with the introduction of mutations in the recombinant 
wild-type protein lowering the efficacy and safety of the therapeutic [194]. Indeed, 
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immunogenicity problems have been reported for the N88R IL-2 mutein (BAY 50-4798) 
leading to ADAs in 27% of treated patients [195]. Another way to reduce side effects and 
immunogenicity and increase efficacy of such IL-2 muteins would be to prolong their half-life 
by PEGylation, coupling to an Fc molecule, to a mAb or a mAb fragment binding to a tumor 
antigen [196]. The strategy of targeting IL-2 to the tumor site could also be tested for the IL-
2/NARA1 complex by engineering a bispecific anti-IL-2 antibody. Such a molecule would 
raise the following questions: Is the IL-2/NARA1 complex specificity conserved? Can the 
protein be targeted to the site of disease, or should the tumor-draining lymphoid organs be 
targeted instead in order to get and sustain a potent immune response? Will it be necessary to 
engineer a smaller molecule (antibody fragments such as diabodies) in order to increase its 
accumulation at the tumor site? On one side one might think that small size molecules are 
able to better reach and stay in the site of disease while being eliminate fast from the body 
brining along less side effects. On the other hand, targeting IL-2 only to the tumor site could 
harm the anti-tumor response obtained with the stimulation of intratumoral Treg cells. The 
efficacy of the therapy could be compromised by the exhaustion levels of the stimulated CD8+ 
T cells being in an immunosuppressive environment. It remains important to test different 
strategies in order to keep a favorable Tc vs Treg cells ratio in the tumor and to balance 
efficacy and toxicity. 
The strategy used for the generation of an anti-IL-2 antibody with in vivo selectivity should be 
applicable to other cytokines including IL-3, IL-4, IL-6, IL-7, IL-15, and granulocyte colony-
stimulating factor, for which in vivo agonist cytokine/antibody complexes have been 
described [197-200]. For example, we recently described polyclonal antibodies to IL-1 
raised in mice that can either inhibit this pro-inflammatory cytokine or enhance its in vivo 
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effect by worsening IL-1 mediated diseases (submitted manuscript entitled ‘Endogenous 
polyclonal anti-IL-1 antibodies potentiate IL-1 activity during pathogenic inflammation’, data 
not shown). 
The IL-2/NARA1-mediated immune stimulation allowing potent tumor control is lost over 
time, likely due to tumor immune escape mechanisms. For this reason, the 2nd part of this 
Ph.D. thesis was focused on investigating the mechanisms involved in tumor immune escape 
during IL-2cx immunotherapy. By analyzing the epigenetic signature in melanoma cells 
following treatment with IL-2-cx, we were able to show that the expression levels of the 
epigenetic regulator Ezh2 increases in melanoma cells during immunotherapy leading to 
dedifferentiation of melanoma cells and silencing of key molecules needed for tumor antigen 
presentation. We hypothesized that by inhibiting EZH2 with GSK503, melanoma cells are 
rendered ‘immunogenic’ again and therefore could be recognized by specific CD8+ T cells 
expanded upon hIL-2/NARA1 complex treatment. This synergy could also be observed using 
an anti-CTLA-4 mAb. These results do not only show the benefit of combining cancer 
immunotherapy with epigenetics blockers but precisely describe the central role of Ezh2 
during tumor immune escape. In addition, our results complement the data obtained by 
Weiping Zou and colleagues showing that in human ovarian cancer cells EZH2 and DNA 
methyltransferase 1-mediated DNA methylation repress tumor production of the chemokines 
CXCL-9 and CXCL-10, essential for the recruitment of effector T cells into the tumor. 
Blocking of such epigenetic pathways restores chemokines levels resulting in higher T cell 
infiltration and better tumor control [187].  
Although many of the downstream targets of EZH2 are linked to tumor development and 
metastasis, it will be important to know which other genes could be further upregulated by 
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EZH2 inhibition to avoid long-term adverse effects. Furthermore, some loss-of-function 
mutations of EZH2 have been linked to hematological malignancies [201, 202], suggesting 
that this enzyme can also play a role in tumor suppression. It remains to be tested if EZH2 
inhibitors are an appropriate treatment in all patients.  
Moreover, it has been recently shown that cancer cells restrict T cell-mediated immunity via 
inhibition of EZH2 expression on T cells by limiting their glycolysis pathway [203]. The 
polyfunctional properties of EZH2+ T cells convey survival advantages to those cells in the 
tumor microenvironment. Likewise, EZH2 expression on T cells correlates with better 
survival and prognosis in patients [203]. EZH2 seems therefore to play opposite roles on T 
cells and tumor cells, questioning systemic administration of epigenetic blockers that could 
potentially target T cell effector functions. Different strategies should be followed and studied 
in order to minimize such risks, such as administering lower doses, targeting epigenetic drugs 
to the tumor cells, or combining epigenetic drugs with other immunotherapy strategies that 
would enhance efficacy as observed using hIL-2/NARA1 complex and EZH2 blockers.  
It would be interesting to assess whether EZH2 overexpression could be used as a biomarker 
defining different clinical forms of melanoma. Likewise, it will be important to understand the 
relationship between EZH2-mediated histone methylation and DNA methylation to know 
whether the inhibition of one pathway is enough to control tumor growth or the combination 
could be beneficial.  
Our data shows that EZH2 plays a central role during tumor immune escape being responsible 
of impaired antigen presentation and expression of immunosuppressive molecules such as 
PD-L1. Nevertheless, it is important to keep in mind that tumor escape is most likely a highly 
complex process and cancer cells could use several strategies to evade the immune system. 
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Down-regulation of adhesion molecules within the tumor tissue might contribute to 
immunological ignorance [204]. When strategies such as vaccination or adoptive transfer of 
anti-tumor T cells are used to ensure proper immune activation, tumors might also escape 
through the expression of immunosuppressive cytokines such as IL-10 or TGF-β known to 
affect the proliferation, activation and differentiation state of immune cells [205, 206]. In 
parallel, tumor cells have been shown to promote the generation of immunosuppressive Treg 
cells, which actively inhibit the action of tumoricidal effector cells [207]. Moreover, the lack 
of a T cell response could be explained by tolerance induction. Although T cells might bind 
via their TCR to a peptide presented on MHC molecules on the surface of the tumor cells, the 
absence of co-stimulatory molecules might still induce T cell anergy [208]. Another tolerance 
mechanism under investigation is a process known as T cell deletion through activation-
induced cell death [209]. It might be that cancer cells can also mutate their expression profile 
of molecules involved in apoptotic signaling making them resistant to cellular cytotoxicity. It 
is logical to think that tumor cells combine and adapt several immune escape mechanisms in 
response to different conditions. Of course, these mechanisms may also depend on the type of 
cancer and on the immune system of every patient. To date, it is clear that there is not a 
unique way to cure cancer. There is a need to get deeper knowledge on every single case 
(patient and cancer type) and to rationally combine the available therapeutics to improve 
current treatments, trying to keep a balance between efficacy and toxicity. 
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VII. Material and methods 
Mice 
3-month-old female C57Bl/6J mice and Balb/c were purchased (Charles River Laboratories). 
Tcrb/d–/–, Rag1–/–, Ifng–/–, Tnfa–/–, IL-7tg.Ly5b and pmelSi Thy1a transgenic mice were acquired 
and maintained according to suppliers recommendations (The Jackson Laboratory). Tyr::N-
RasQ61K Ink4a–/– transgenic mice were mated, genotyped and monitored for tumor 
development as previously described [170]. All mice were of a C57Bl/6 background, born 
with the expected ratio of Mendelian inheritance and no changes in gender ratios were 
observed. No statistical methods were used to predetermine sample size. For all experiments 
presented in this study, the sample size was large enough to measure the effect size. The 
experiments were not randomized and the investigators were not blinded to allocation during 
experiments and outcome assessment. Mouse colonies were maintained in certified animal 
facilities in accordance with Swiss guidelines. All animal experiments were approved by the 
veterinary authorities of Canton of Zurich, Switzerland, and were performed in accordance 
with Swiss law and the GlaxoSmithKline policy on the Care, Welfare, and Treatment of 
Animals. Pre-established exclusion criteria were based on the Canton of Zurich veterinary 
authority's guidelines and included substantial weight loss of >15% of initial body weight. 
During the study period most of the animals appeared to be in good health. 
Generation of anti-human IL-2 mAbs 
Balb/c mice were immunized with human (h) IL-2 (34-8029, eBioscience) in Freund’s 
adjuvant (F-5881, Sigma) on days 0, 14 (subcutaneously) and 28 (intravenously). Serum was 
collected before the first immunization and 9–11 days after every immunization in order to 
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check for anti-hIL-2 antibody titers. On day 35, mice were euthanized and spleen cells were 
collected following standard procedures. Splenocytes were mixed with myeloma cells at a 5:1 
ratio with polyethylene glycol 1500 (10783641001, Roche). A feeder layer obtained from 
peritoneal lavage of Balb/c mice was used to grow clones in IMDM selective media (21980, 
Life Technologies) supplemented with 10% ultra-low IgG FBS (16250, Life Technologies), 
50 μM mercaptoethanol (313050, Life technologies), 1:100 Insulin-Transferrin-Selenium 
(41400-045, Life Technologies), 2% IL-6-conditioned media, penicillin-streptomycin (15240, 
Life Technologies), gentamycin (15750, Life Technologies), and  hypoxanthine-aminopterin-
thymidine (HAT, H037, Sigma-Aldrich) for several days. Polyclonals were then screened for 
hIL-2 binding using a direct binding ELISA and for specificity using a competition ELISA, as 
shown in Fig. S1, and diluted to obtain monoclonal clones. For expansion of monoclonals, 
HAT media was replaced by hypoxanthine-thymidine media (HT, 41065, Life Technologies). 
Monoclonals were then concentrated using 100 kDa centrifugal filter units according to 
supplier’s recommendations (UFC9100, Merck Millipore). Concentrate was further tested for 
specificity in a dose-dependent manner using a competition ELISA and in vivo using 4 daily 
intraperitoneally injections of 200 μl concentrate complexed with 1.5 μg hIL-2, followed by 
assessment by flow cytometry of T cell subsets and natural killer (NK) cells, as shown in Fig. 
S1. NARA1 was purified using Protein G agarose (20398. ThermoFisher Scientific) according 
to supplier’s recommendations. 
Surface plasmon resonance (SPR) binding and titration experiments 
100 μg/ml NARA1 or 5344 (clone 5433.111, BD Biosciences) antibodies were immobilized 
into a GLM-Chip according to supplier’s recommendations (176-5012, BioRad), followed by 
addition of hIL-2 (34-8029, eBioscience) at titrated concentrations in 3-fold dilutions starting 
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at 100 nM. For hCD25 and hCD122 titration experiments, hIL-2 was added at saturating 
concentration (1 M) followed by coinjection of recombinant hCD25 or hCD122 (223-
2A/CF, 224-2B/CF, R&D Systems) in 3-fold dilutions starting at 1 M. 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Flat Nunc-Immuno 96-well plates (M9410-1CS, Sigma-Aldrich) were coated overnight at 
4°C with recombinant hIL-2 (direct binding ELISA; hIL-2, eBioscience, 34-8029) or with 
purified capture anti-hIL-2 mAb (competition ELISA, mAbcap, clone 5344.111, BD) in PBS. 
The plates were then washed with PBS-Tween (0.1% Tween 20, P1379, Sigma-Aldrich) and 
blocked for at least 1 hour at room temperature (RT) in 1% BSA (A2058, Sigma-Aldrich), 0.1 
% Tween solution at 450 rpm. After washing, hybridoma supernatants (direct ELISA) or hIL-
2 (competition ELISA) were added to the plates in blocking solution and incubated for 1 hour 
at RT and 450 rpm, followed by washing. To check competition for a specific epitope, titrated 
amounts of hybridoma supernatants (concentrate) or purified NARA1 mAb, Fab or (Fab’)2 
fragments were added. The plates were washed before addition of biotinylated anti-mouse 
IgG (direct ELISA, 405303, Biolegend) or biotinylated anti-hIL-2 detection mAb 
(competition ELISA, mAbdet, clone 5355, R&D systems) to the plates for 1 hour at RT and 
450 rpm. Plates were then washed and streptavidin-conjugated horseradish peroxidase was 
added for 45 minutes at RT (554066, BD Biosciences) and, after a final vigorous wash, plates 
were developed using the single-component TMB Peroxidase EIA substrate (172-1068, 
BioRad). After 5–10 minutes the reaction was stopped by addition of 1.8 M H2SO4 (339741, 
Sigma-Aldrich) and readout was performed at 450 nM absorbance using an iMark microplate 
reader (BioRad). Biotinylation was performed using the EZ-link Sulfo-NHS.LC Biotinylation 
kit (21435, Thermo Scientific) according to supplier’s recommendations. 
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Complexing of hIL-2 with NARA1 mAb, Fab, and F(ab')2 
The antigen, Proleukin, is commercially available as lyophilized powder and was purified by 
reverse-phase HPLC to remove the excipients before use for complex formation. The Fab 
fragment of NARA1 was generated by papain cleavage of the full-length monoclonal 
antibody (mAb) followed by Protein A chromatography. Briefly, 6.5 ml full-length NARA1 
(9 mg/ml in 50 mM citrate buffer with 90 mM sodium chloride at pH 7.0) was mixed with 5 
mM DTT and 590 g Papain (Roche). The cleavage reaction was kept at room temperature 
for 16 hours and stopped by addition of 15 l 56 mM E64 solution (Roche). The cleavage 
solution was then diluted 10 times with 25 mM Tris, 25 mM NaCl, pH 8.0 and purified using 
a 5 ml Protein A column (GE Healthcare) to remove Fc fragments. For generation of NARA1 
F(ab')2 fragments, about 5 mg of NARA1 mAb were digested overnight at 37°C with 5000 U 
IdeS protease (Genovis). Incompletely digested mAb and Fc fragments were removed using a 
1 ml Protein A column. IdeS was then removed by size exclusion on Superdex 200 (GE 
Healthcare) run in PBS. To form hIL-2/NARA1 Fab complex for crystallization, Proleukin 
powder after HPLC was dissolved in H2O at a concentration of 5.5 mg/ml. 6.6 mg Proleukin, 
in excess, was added to 11.5 mg NARA1 Fab fragment solution drop by drop. Centrifugation 
was used to remove excess Proleukin that precipitated under these conditions. The complex 
was then purified by gel filtration with Superdex 200 10x300 using a running buffer of 25 
mM Tris and 25 mM NaCl at pH 7.4. 
 
 105 
 
Crystallization and data collection and analysis 
Proleukin/NARA1 Fab complex after gel filtration was concentrated to 14 mg/ml and 
screened with vapour diffusion method as sitting drops. The protein solution was mixed 1:1 
with reservoir buffer to a total size of 0.4 l and crystallization plates were kept at 19°C. 
Crystals were harvested 4 days after screening under condition of 20% w/v polyethylene 
glycol 3350 and 0.2 M sodium nitrate. Crystals were cryoprotected using reservoir buffer plus 
10% glycerol and flash frozen in liquid nitrogen prior to data collection. Diffraction data were 
collected at the Swiss Light Source (Villigen, Switzerland) at beam-line PX-II with a Pilatus 
pixel detector using X-ray radiation wavelength of 0.99998 Å. The dataset was processed with 
XDS and XSCALE (version Dec. 6, 2010) and the structure was resolved with molecular 
replacement method with the program PHASER by using Protein Data Bank (PDB) entry 
“3INK” as search model for hIL-2 and PDB entry “3TTI” as search model for Fab fragment. 
Iterative model building and refinement were performed with the programs Coot and 
AUTOBUSTER. All figures were generated with the program PyMOL. Proleukin residues 
were defined as residues that were within 4 Å distance from any atom of the NARA1 Fab and 
were further confirmed by CCP4 program CONTACT and AREAIMOL. Similarly, paratope 
residues were defined as those residues of NARA1 Fab that were within 4 Å distance from 
any atom in Proleukin. 
Linear peptide mapping 
Linear peptide mapping experiments were performed, as previously described [210]. Briefly, 
a library of 15-mer peptides was generated based on the sequence of hIL-2, followed by 
generation of a second library with 3 defined mutations on residues F42, Y65 and L92, based 
on available IL-2 muteins [55]. Peptides were designed thus each contained 12 overlapping 
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residues with the previous peptide and 12 with the following peptide. In total 41 peptides 
were generated, but only the 9 most prominent ones as shown. In order to avoid unspecific 
binding the cysteines of all peptides were replaced by a serine. The peptides were printed on 
microarray slides in triplicates and incubated with mAbdet, NARA1 or isotype control mAbs. 
Antibodies were then detected using fluorescently-labeled anti-mouse IgG antibodies (85454, 
Thermo Scientific, label DL650 or JIR 115-072, label Cy5). All steps were performed on a 
TECAN microarray processing station. After incubation of the mAbs and final washing the 
microarray were dried using nitrogen steam and scanned. The resulting images were analyzed 
using spot-recognition software GenePix (Molecular Devices), and the mean signal intensity 
was extracted for each spot. 
Cell cultures 
Sp2/0 myeloma cell line and IL-6 producing cell line were kindly provided by Antonius 
Rolink (University of Basel, Switzerland) and cultured in the media described above for the 
generation of mAbs. B16-F10 melanoma and CTLL-2 cell lines were purchased (ATCC). 
Cells were cultured in growth medium, which was RPMI 1640 (42401, Life Technologies) 
supplemented with 10% FCS (16140, Life Technologies), 4 mM L-Glutamine (25030, Life 
Technologies), Penicillin-Streptomycin (15070, Life Technologies), and Fungizone 
Antimycotic (15290, Life Technologies).  
To stably silence Ezh2, cells were transfected with small hairpin RNA (shRNA)-expressing 
plasmids encoding either a scrambled shRNA (shCo, SHC002, Sigma-Aldrich) or an Ezh2 
mRNA-targeting shRNA (shEzh2, TRCN0000039040, Sigma-Aldrich). 10 μg plasmid was 
applied in combination with jetPEI DNA Transfection Reagent (101-10N, Polyplus 
Transfection) according to manufacturer’s guidelines. Transfected cells were selected using 1 
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μg/ml puromycin (A11138-02, Life Technologies) for 1 week before subjection to further 
assays. To pharmacologically inhibit Ezh2, cells were treated with 1 M GSK503 for 8 days 
before subjection to further assays. Drug was only replenished when cells were passaged 
during the 8-day period. Efficiency of shEzh2 and GSK503 has been previously validated 
[170, 173, 211].  
Human leukocytes were freshly isolated from peripheral blood mononuclear cells (PBMCs) 
using a standard Ficoll density gradient isolation protocol, maintained in growth media (as 
described above) supplemented with 10 % human serum, followed by purification of  T cell 
subsets using kits (130-045-201, CD8 human Microbeads, Miltenyi Biotec). 
In vitro proliferation 
CTLL-2 cells were seeded into 96-well plates (10 000 cells/well) and stimulated using mIL-2 
(34-8021, eBiosciences), mIL-2/S4B6 complex (2:1 molar ratio; BioXcell), hIL-2, or hIL-
2/NARA1 complex (2:1 molar ratio), and proliferation was assessed after 48 hours incubation 
at 37°C. After 72 hours at 37°C in complete medium, purified human CD8+ T cells were 
seeded in 96-well plates (75 000 to 100 000 cells/well) and stimulated with hIL-2 or hIL-
2/NARA1 complex (at a 2:1 molar ratio). Proliferation was assessed after 96 hours incubation 
at 37°C. Proliferation was measured using WST-1 (11644807001, Sigma-Aldrich), added to 
the cells. After 4 hours of incubation at 37°C readout was performed at 450 nM absorbance 
using an iMark microplate reader (BioRad). 
STAT5 phosphorylation 
CTLL-2 cells (200 000 cells/well) or purified human CD8+ T cells were seeded in a 96-well 
plate (400 000 cells/well) and stimulated using hIL-2 or hIL-2/NARA1 complex (at a 2:1 
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molar ratio). Phosphorylation of STAT5 was assessed after 15 minutes of stimulation, as 
previously described [142], and using manufacturer’s buffer recommendation for human cells 
(612599, BD Phosflow Protocol for Human PBMCs, STAT5 antibody, BD Biosciences). 
Grafting of murine melanoma cells 
Skin melanoma cells derived from a Tyr::N-RasQ61K Ink4a–/– mouse (RIM-3) were previously 
analysed [170]. Recipient mice were intradermally or subcutaneously engrafted with either 
500 000 RIM-3 cells or 1 x 106 B16-F10 cells. Mice engrafted with melanoma cells were 
sacrificed not later than at a time point defined by tumor volume (V > 1’000 mm3). Tumor 
volume was calculated as follows: V = 2/3 × π × ((a + b)/4)3, a (mm) was the length and b 
(mm) was the width of the tumor. For pulmonary tumor nodules, 3 x 105 B16-F10 melanoma 
cells were injected intravenously in 100 l DMEM. 
In vivo treatments 
Recombinant hIL-2 (IL-2, Teceleukin, Roche), anti-CTLA-4 mAb (9D9, BioXcell), anti-PD-1 
mAb (RMP1-14, BioXcell), anti-CD8 mAb (YTS169, BioXcell), anti CD4-mAbs (GK1.5, 
BioXcell) and GSK503 (GlaxoSmithKline) were purchased. hIL-2/NARA1 antibody complex 
(IL-2cx) was prepared in PBS by mixing 1.5 g hIL-2 and 15 g NARA1 antibody, as 
previously described [60, 133, 134]. GSK503 was diluted (15 mg/ml) in 20% Captisol 
solution (Cydex). Treatment of B16-F10 tumor-bearing mice was started, for intradermal 
tumors, when tumors became visible and palpable (usually day 4 ± 1 day) and, for pulmonary 
tumors, 3 days after B16-F10 injection and consisted of 4 daily injections of phosphate-
buffered saline (PBS), hIL-2, or hIL-2/NARA1. For lung tumors, mice were killed on day 16 
and lungs fixed for counting pulmonary melanoma nodules, as previously described [60]. 
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Treatment of RIM-3-engrafted mice was induced when tumors reached a considerable size (V 
> 150 mm3, ~20 days). Ezh2 inhibition has been previously defined [170, 173] and was 
achieved by daily intraperitoneal injections of 150 mg/kg GSK503 until termination of the 
experiment. Where indicated, mice received intraperitoneal injections of IL-2cx, 250 g of 
anti-CTLA-4 mAb, or 250 μg of anti-PD-1 mAb for four consecutive days. To deplete T cells, 
500 μg anti-CD8 mAb (YTS169, BioXcell) or 250 μg anti CD4-mAbs (GK1.5, BioXcell) 
were injected intraperitoneally to B16-F10-engrafted mice starting on the day of tumor 
engraftment. Treatment of Tyr::N-RasQ61K Ink4a–/– mice, consisting of 4 consecutive 
injections of hIL-2/NARA1 complex weekly, was started at the age of three months, before 
macroscopic skin melanomas were visible. Mice were monitored weekly for the appearance 
of macroscopic tumors (diameter>1.5mm). Quantifications of skin melanomas and metastases 
were done, as previously described [170]. 
Where indicated CD90.1+ Pmel-specific CD8+ T cells were obtained from pooled spleen and 
lymph nodes of PmelSi Thy1a transgenic mice and purified using negative T cell enrichment 
(19853, StemCell Technologies). At least 2 x 106 purified cells were adoptively transferred to 
recipients. To assess IL-2-induced toxicity, mice received 4 consecutive injections of hIL-2 at 
1.5 g (low dose; LD) or 20 g (high dose; HD), 15 g NARA1, or hIL-2/NARA1 (1.5 g 
and 15 g, respectively). One day after the last injection, mice were sacrificed and pulmonary 
wet weight was determined as previously described [60]. To determine immune cell 
proliferation, two methods were used: 
 CD8+ T cells, obtained from pooled LNs of IL-7-transgenic mice (IL-7tg.Ly5b) on a 
Ly5.1 background, were labelled with carboxyfluorescein succinimidyl ester (CFSE, 
C1157; ThermoFisher), as previously described [134]. At least 2 x 106 purified cells 
were adoptively transferred to recipients, followed by 4 daily injections of PBS, hIL-2, 
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or hIL-2/NARA1 complex. IL-7-transgenic mice were used since they have an 
increase in T cell numbers especially at the level of memory phenotype 
CD44highCD122high CD8+ T cells. 
 Bromodeoxyuridine (BrdU; B5002, Sigma-Aldrich) was given to mice in drinking 
water (0.8 mg/ml). BrdU-incorporated cells were labelled using the FITC BrdU Flow 
Kit (557891, BD Biosciences) according to manufacturer’s instructions. 
Flow Cytometry 
Single cell suspensions of lymph nodes and spleen were prepared according to standard 
protocols. Tumors were cut into small pieces, pooled per groups in order to obtain enough 
cells for analysis, and incubated in 10 ml dissociation buffer (RPMI, 5% FCS, 10 g/ml of 
DNAase I (D4527, Sigma-Aldrich) and 200 U/ml of collagenase type I (17100-017, Life 
Technologies) for 45 minutes at 37°C and 25 rpm. Cell suspension was then passed through a 
70 μm cell strainer. After one wash a Percoll (17-5445-01, GE Healthcare) gradient 
centrifugation was performed. All cell suspensions were stained for flow cytometry analysis 
using PBS with 2% FCS, 2 mM EDTA and fluorochrome-conjugated Abs (Supplementary 
Table 1). Intracellular CD107a, FoxP3, IFN-γ, and TNF- stainings were performed 
following manufacturers' instructions after in vitro restimulation using PMA and ionomycin 
(0.1 mg/ml and 1 mg/ml, P8139 and I0634, Sigma-Aldrich) or gp100 short peptide (10 nM; 
generated, purified, dissolved and stored as described previously [212] ) in the presence of 
brefeldin A and monensin (2 mg/ml, B7651 and M5273, Sigma-Aldrich). Samples were 
acquired with a BD LSR II flow cytometer (BD Biosciences) and analysed using FlowJo 
software. 
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Histological analysis and immunofluorescence 
Mouse tumor samples were fixed in 4% buffered formaldehyde, embedded in paraffin, sliced 
into 5 m sections, and subjected to immunofluorescent stainings as described before [213]. 
Briefly, sections were deparaffinised and subjected to an antigen-unmasking step in citrate 
buffer (S2369, Dako) using a vegetable steamer for 20 minutes. To minimize unspecific Ab 
binding, sections were subjected to two blocking steps using UltraVision Protein Block (TA-
060-PBQ, Thermo Scientific) for 5 minutes and subsequently an immunofluorescence 
blocking buffer (0.2% BSA, 0.2% gelatin A, 0.2% casein, and 0.2% Triton X-100 in TBS) for 
15 minutes at room temperature. Primary Abs (Supplementary Table 2) were applied in 
Antibody Diluent (S0809, Dako) overnight at 4°C and visualized using secondary Abs 
(Supplementary Table 3) in Antibody Diluent for 1 hour at room temperature. Subsequently, 
nuclei were stained with Hoechst 33342 (14533, Sigma-Aldrich) and slides were mounted 
with Fluorescent Mounting Medium (S3023, Dako). Immunofluorescent sections were 
recorded using a DMI 6000B microscope (Leica) and fluorescence intensity was quantified 
with CellProfiler software [214]. For tumor sections derived from PBS- or GSK503-treated 
mice, at least 10 fields containing n ≥ 1 CD45+ or CD3+ cells were quantified. For tumor 
sections derived from IL-2cx or GSK503 + IL-2cx-treated mice, at least 10 fields containing 
either n < 5 or n > 25 CD45+ or CD3+ cells were quantified. Ezh2high cells were defined as 
previously described [170]. 
Immunofluorescence on cells 
Cells were grown on cover slips, fixed with 50% ethanol, and subjected to immunofluorescent 
labelling using primary Abs (Supplementary Table 2) in blocking buffer (1% BSA in PBS) 
overnight at 4°C and secondary Abs (Supplementary Table 3) for 1 hour at room temperature. 
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Nuclei were stained with Hoechst 33342 and cells were recorded with a DMI 6000B 
microscope. 
 
 
RNA isolation and RT-qPCR 
Cells were lysed in Buffer RLT (79216, Qiagen) containing 1% 2-mercaptoethanol, while 
tumor biopsies were homogenised in such buffer using a Polytron PT 2100 tissue disperser 
(Kinematica). Subsequent RNA extraction and DNase treatment of samples was performed 
using the RNeasy Mini Kit (74104, Qiagen) and the RNase-Free DNase Set (79254, Qiagen) 
according to manufacturer’s guidelines. Purified RNA was quantified using a NanoDrop ND-
1000 Spectrophotometer (Thermo Scientific) and subjected to reverse transcriptase reaction 
using the Maxima First Strand cDNA Synthesis Kit (K1641, Thermo Scientific) followed by 
an RNase H (EN0202, Thermo Scientific) digestion step according to manufacturer’s 
recommendations. Quantitative real-time PCR was performed on a LightCycler 480 System 
(Roche) using LightCycler 480 SYBR Green I Master (4707516001, Roche). Primers used are 
indicated in Supplementary Table 4. Each sample was analysed in technical triplicates, and 
relative quantified RNA was normalized using Usf1 as housekeeping transcript. 
Chromatin isolation and ChIP 
Chromatin isolation and chromatin immunoprecipitation (ChIP) was performed using the 
SimpleChIP Plus Enzymatic Chromatin IP Kit (9005, Cell Signaling Technology) according 
to manufacturer’s guidelines. Briefly, tumor biopsies of 150 mg were minced using razor 
blades and scissors and subjected to chromatin isolation. Crosslinked samples were 
disaggregated into single cells using a Polytron PT 2100 tissue disperser. Isolated nuclei were 
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digested with 5 l micrococcal nuclease for 30 minutes at 37°C and nuclei were lysed using a 
SONOPULS HD 2070 Ultrasonic Homogenizer (Bandelin). Chromatin digestion efficiency 
was verified by agarose gel electrophoresis and chromatin concentration was determined with 
a NanoDrop ND-1000 Spectrophotometer. The ChIP was performed with 18 g chromatin 
and primary Abs indicated in (Supplementary Table 2). Quantitative real-time PCR was 
performed on a LightCycler 480 System using the KAPA SYBR Fast qPCR Kit Master Mix 
(KR0389, KAPA Biosystems). Primers were designed to amplify genomic DNA from a 
region flanking the transcriptional starting site -500 bp to +100 bp devoid of local CpG 
islands defined by CpG island prediction [215]. Primers used are indicated in (Supplementary 
Table 5). Relative promoter enrichment was normalised to chromatin inputs and to the 
intergenic region 1 (Interg1), which was previously defined as a negative control [216]. 
Protein isolation and Western blotting 
For protein isolation, tumor biopsies were homogenised in RIPA buffer (89900, Thermo 
Scientific) containing Halt Phosphatase and Protease Inhibitor Cocktails (78420 and 87786, 
Thermo Scientific) using a Polytron PT 2100 tissue disperser. Cell lysis was completed using 
a SONOPULS HD 2070 Ultrasonic Homogenizer. Total protein concentration was 
determined with the BCA Protein Assay Kit (23227, Thermo Scientific) using a DTX 880 
Multimode Detector (Beckman Coulter). Western blotting was performed as previously 
described  [170]. Briefly, SDS–PAGE was carried out on 4–20% Mini-PROTEAN TGX Gels 
(456–1094, Bio Rad). Primary Abs (Supplementary Table 2) were applied in Odyssey 
blocking buffer (927–40000, LI-COR Biosciences) overnight at 4°C and visualized using 
secondary Abs (Supplementary Table 3) in Odyssey blocking buffer for 45 minutes at room 
temperature. Blots were scanned and quantified with an Odyssey imaging system (LI-COR 
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Biosciences). Quantified band intensities were normalized using either -Actin or Histone 3 
as housekeeping protein. 
 
 
Statistical analyses 
P-values were calculated as indicated using either analysis of variance (ANOVA), Fisher’s 
least significant difference (LSD) test, or a two-sided unpaired Student’s t-test. The expected 
variance was similar between the groups that were compared.  
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